Powder containing 5-aminolevulinic acid or salt thereof and method for producing same

The impact grinding method for 5-aminolevulinic acid or its salts produces a powder with uniform particle size and solvent content, addressing uniformity issues in conventional methods, enhancing dispersibility and stability for pharmaceutical and supplement applications.

WO2026239691A1PCT designated stage Publication Date: 2026-11-19KYOWA HAKKO BIO CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2026/003047
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-01-29
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Conventional methods for producing 5-aminolevulinic acid or its salts result in powders with insufficient uniformity of physical properties, affecting the stability and quality of products such as supplements and pharmaceuticals.

Method used

The production method involves pulverizing 5-aminolevulinic acid or its salts using impact grinding to achieve a powder with an average particle diameter of 230 μm or less, a standard deviation of 110 μm or less, and a residual organic solvent content of 1000 ppm or less, utilizing a high-speed rotary grinder like a pin mill.

Benefits of technology

The resulting powder exhibits enhanced uniformity, improved dispersibility, stability, and reduced variability, making it suitable for consistent product quality and ease of handling as a raw material.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-T000001
    Figure JPOXMLDOC01-APPB-T000001
  • Figure JPOXMLDOC01-APPB-T000002
    Figure JPOXMLDOC01-APPB-T000002
  • Figure JPOXMLDOC01-APPB-T000003
    Figure JPOXMLDOC01-APPB-T000003
Patent Text Reader

Abstract

A powder containing 5-aminolevulinic acid or a salt thereof having an average particle size of 230 μm or less and a standard deviation of 110 μm or less, calculated based on the number of particles in a particle size distribution, can be produced by a production method including a step for pulverizing crystals of 5-aminolevulinic acid or a salt thereof by impact-type pulverization. The powder is unlikely to undergo variations in quality even when mass-produced and is useful as a raw material for products such as supplements and medicines. Also, a powder containing 5-aminolevulinic acid or a salt thereof having an ethanol content of 1000 mass ppm or less can be produced by the production method.
Need to check novelty before this filing date? Find Prior Art

Description

Powder containing 5-aminolevulinic acid or a salt thereof and method for producing the same

[0001] This disclosure relates to a powder containing 5-aminolevulinic acid or a salt thereof and a method for producing the same.

[0002] 5-aminolevulinic acid (hereinafter abbreviated as 5-ALA) is expected to have applications as a food and pharmaceutical active ingredient. Methods for producing 5-aminolevulinic acid include chemical synthesis and fermentation using genetically modified microorganisms (Patent Documents 1 and 2).

[0003] In either method, crystallization using a poor solvent is performed in the step of purifying 5-aminolevulinic acid (Patent Documents 3-5).

[0004] Since 5-aminolevulinic acid is used as a raw material for supplements and pharmaceuticals, it is desirable that the physical properties of 5-aminolevulinic acid crystals be uniform. For example, if capsule filling or tableting is performed using powder with uniform physical properties and a low standard deviation (variation) in particle size, it is possible to produce products of stable quality.

[0005] Patent No. 2997979 Patent No. 4520219 Patent No. 4915723 Patent No. 4989153 Patent No. 5845203

[0006] However, in conventional methods for producing powder of 5-aminolevulinic acid or its salts, the uniformity of the powder's physical properties was insufficient.

[0007] Therefore, this disclosure aims to address the above-mentioned problems and provide a powder containing 5-aminolevulinic acid or a salt thereof with uniform powder properties, and a method for producing the same.

[0008] The inventors of the present invention have discovered that in the production of a powder containing 5-aminolevulinic acid or a salt thereof, a powder containing 5-aminolevulinic acid or a salt thereof with uniform powder properties can be obtained by pulverizing the crystals of 5-aminolevulinic acid or a salt thereof by impact pulverization, and have completed the present invention.

[0009] In other words, the present disclosure is as follows: <1> A powder containing 5-aminolevulinic acid or a salt thereof, wherein the average particle diameter calculated based on the number of particles in the particle size distribution is 230 μm or less and the standard deviation of the particle diameter in the particle size distribution is 110 μm or less. <2> The powder according to <1>, wherein the crude specific volume is 3.0 mL / g or less. <3> The powder according to <1> or <2>, wherein the dense specific volume is 2.0 mL / g or less. <4> The powder according to any one of <1> to <3>, wherein the content of each organic solvent is 1000 ppm by mass or less. <5> The powder according to <4>, wherein the organic solvent is at least one selected from ethanol, methanol, isopropanol, n-propanol, acetone, and acetonitrile. <6> The powder according to any one of <1> to <5>, wherein the ethanol content is less than 1000 ppm by mass. <7> A method for producing a powder containing 5-aminolevulinic acid or a salt thereof, comprising the following steps (1) and (2). (1) A step of preparing crystals of 5-aminolevulinic acid or a salt thereof. (2) A step of grinding the crystals of 5-aminolevulinic acid or a salt thereof prepared in step (1) above by impact grinding. <8> The manufacturing method according to <7>, wherein the impact grinding above is grinding by a high-speed rotary grinder. <9> The manufacturing method according to <8>, wherein the high-speed rotary grinder above is a fine grinder. <10> The manufacturing method according to <9>, wherein the fine grinder above is a pin mill. <11> The manufacturing method according to any one of <7> to <10>, wherein the average particle diameter calculated based on the number of particles in the particle size distribution of the powder is 230 μm or less and the standard deviation of the particle diameter in the particle size distribution above is 110 μm or less. <12> The manufacturing method according to any one of <7> to <11>, wherein the crude specific volume of the powder is 3.0 mL / g. <13> The manufacturing method according to any one of <7> to <12>, wherein the dense specific volume of the powder is 2.0 mL / g. <14> The manufacturing method according to any one of <7> to <13>, wherein the step (1) above includes crystallization using an organic solvent, and the content of each of the organic solvents remaining in the powder is less than 1000 ppm by mass. <15> The manufacturing method according to <14>, wherein the organic solvent is at least one selected from methanol, ethanol, isopropanol, n-propanol, acetone, and acetonitrile.<16> The manufacturing method according to <14>, wherein the organic solvent is ethanol. <17> The powder according to any one of <1> to <6>, wherein 5-aminolevulinic acid or a salt thereof is 5-aminolevulinic acid phosphate. <18> The manufacturing method according to any one of <7> to <16>, wherein 5-aminolevulinic acid or a salt thereof is 5-aminolevulinic acid phosphate.

[0010] <101> A powder of 5-aminolevulinic acid or a salt thereof having a particle size of 230 μm or less and a standard deviation of 110 μm or less. <102> The powder according to <101>, having a crude specific volume of 3.0 mL / g or less and a standard deviation of 0.4 mL / g or less. <103> The powder according to <101> or <102>, having a dense specific volume of 2.0 mL / g or less and a standard deviation of 0.1 mL / g or less. <104> The powder according to any one of <101> to <103>, having a powder residual organic solvent content of 1000 ppm or less. <105> The powder according to <104>, wherein the organic solvent is at least one selected from ethanol, methanol, isopropanol, n-propanol, acetone, and acetonitrile. <106> The powder according to <104>, wherein the organic solvent is ethanol. <107> A method for producing a powder of 5-aminolevulinic acid or a salt thereof having a particle size of 230 μm or less and a standard deviation of 110 μm or less, comprising the following steps (1) and (2): (1) A step of preparing a powder of 5-aminolevulinic acid or a salt thereof; (2) A step of grinding the powder of 5-aminolevulinic acid or a salt thereof prepared in step (1) by impact grinding. <108> The method according to <107>, wherein the impact grinding is grinding by a high-speed rotating machine. <109> The method according to <108>, wherein the high-speed rotating machine is a fine grinder. <110> The method according to <109>, wherein the fine grinder is a pin mill. <111> The method according to any one of <107> to <110>, wherein the standard deviation of the crude specific volume of the powder at 3.0 mL / g is 0.4 mL / g or less. <112> The manufacturing method according to <107> to <111>, wherein the dense specific volume of the powder is 2.0 mL / g and the standard deviation of that volume is 0.1 mL / g or less. <113> The manufacturing method according to any one of <107> to <112>, wherein the content of residual organic solvent in the powder is 1000 ppm or less. <114> The manufacturing method according to <113>, wherein the organic solvent is at least one selected from methanol, ethanol, isopropanol, n-propanol, acetone, and acetonitrile. <115> The manufacturing method according to <113>, wherein the organic solvent is ethanol.

[0011] The powder containing 5-aminolevulinic acid or its salt according to this disclosure has more uniform powder properties than conventional powders, and can improve uniform dispersibility in formulations and stability in formulation. In one embodiment of the powder containing 5-aminolevulinic acid or its salt according to this disclosure, the organic solvent content is reduced, resulting in high purity and ease of handling as a product. Furthermore, the powder containing 5-aminolevulinic acid or its salt according to this disclosure is less prone to quality variations even when mass-produced, making it useful as a raw material for products such as supplements and pharmaceuticals. The manufacturing method according to this disclosure allows the above powder to be produced in a simple procedure.

[0012] The following is a detailed description of this disclosure, but these are merely examples of desirable embodiments and are not limiting to these.

[0013] In the following explanation, the "~" in a numerical range indicates a range that includes the numbers before and after it. For example, "0 mass% to 100 mass%" means a range that is 0 mass% or greater and 100 mass% or less. In this specification, "powder" and "powdered material" are used interchangeably.

[0014] [1] Powder containing 5-aminolevulinic acid or a salt thereof In this disclosure, 5-aminolevulinic acid may be contained in the powder as a salt of 5-aminolevulinic acid. Examples include salt forms such as phosphate, hydrochloride, and nitrate. Among these, phosphate is preferred from the viewpoint of use in food products, etc., as it has excellent storage stability and is less irritating. Examples of powder containing 5-aminolevulinic acid or a salt thereof in this disclosure (hereinafter also referred to as "powder of this disclosure") include powder containing 5-aminolevulinic acid or a salt thereof.

[0015] <Powder Properties> The powder containing 5-aminolevulinic acid or a salt thereof according to this disclosure preferably has an arithmetic mean particle diameter of 230 μm or less, calculated based on the number of particles in the particle size distribution. An average particle diameter of 230 μm or less improves mixability and packability in the formulation process and suppresses variations in product quality. The upper limit of the average particle diameter may be 180 μm or less, 140 μm or less, 110 μm or less, 100 μm or less, 90 μm or less, 88 μm or less, etc. The lower limit of the average particle diameter is preferably 30 μm or more, from the viewpoint of improving storability, processability and degradability, as well as increasing adsorption effect and storage capacity. The lower limit of the average particle diameter may be 40 μm or more, 50 μm or more, 60 μm or more, 67 μm or more, 70 μm or more, 72 μm or more, etc.

[0016] The above average particle diameter range may be any combination of the above lower and upper limits, for example, 70 μm or more and 90 μm or less. In one embodiment, the average particle diameter may be, for example, 30 μm or more and 230 μm or less, 30 μm or more and 180 μm or less, 30 μm or more and 140 μm or less, 30 μm or more and 110 μm or less, 30 μm or more and 100 μm or less, 30 μm or more and 90 μm or less, 30 μm or more and 88 μm or less, 40 μm or more and 230 μm or less, 40 μm or more and 180 μm or less, 40 μm or more and 140 μm or less, 40 μm or more and 110 μm or less, 40μm or more and 100μm or less, 40μm or more and 90μm or less, 40μm or more and 88μm or less, 50μm or more and 230μm or less, 50μm or more and 180μm or less, 50μm or more and 140μm or less, 50μm m or more and 110 μm or less, 50 μm or more and 100 μm or less, 50 μm or more and 90 μm or less, 50 μm or more and 88 μm or less, 60 μm or more and 230 μm or less, 60 μm or more and 180 μm or less, and 60 μm or more 140μm or less, 60μm or more and 110μm or less, 60μm or more and 100μm or less, 60μm or more and 90μm or less, 60μm or more and 88μm or less, 67μm or more and 230μm or less, 67μm or more and 180 μm or less, 67 μm to 140 μm, 67 μm to 110 μm, 67 μm to 100 μm, 67 μm to 90 μm, 67 μm to 88 μm, 70 μm to 230 μm Below, the ranges are 70 μm to 180 μm, 70 μm to 140 μm, 70 μm to 110 μm, 70 μm to 100 μm, 70 μm to 88 μm, 72 μm to 230 μm, 72 μm to 180 μm, 72 μm to 140 μm, 72 μm to 110 μm, 72 μm to 100 μm, 72 μm to 90 μm, and 72 μm to 88 μm.

[0017] The standard deviation of particle size of the powder disclosed herein is preferably 110 μm or less as the arithmetic standard deviation of particle size in the particle size distribution. A standard deviation of 110 μm or less suppresses the variation in particle size distribution, improving solubility and mixability. The upper limit of the above standard deviation of particle size may be 100 μm or less, 90 μm or less, 85 μm or less, 80 μm or less, 75 μm or less, 71 μm or less, etc. From the viewpoint of uniform solubility, a lower standard deviation of particle size of the powder disclosed herein is preferable, and there is no particular lower limit. It may be 0 μm or more, but it may be 10 μm or more, 20 μm or more, 40 μm or more, 50 μm or more, or 54 μm or more, etc.

[0018] The range of the standard deviation of the particle size described above may be any combination of the lower and upper limits described above, for example, it may be 50 μm or more and 75 μm or less. In another embodiment, the standard deviation of particle size is, for example, 0 μm to 110 μm, 0 μm to 100 μm, 0 μm to 90 μm, 0 μm to 85 μm, 0 μm to 80 μm, 0 μm to 75 μm, 10 μm to 110 μm, 10 μm to 100 μm, 10 μm to 90 μm, 10 μm to 85 μm, 10 μm to 80 μm, 10 μm to 75 μm, 10 μm to 71 μm, 20 μm to 110 μm, 20 μm to 100 μm, 20 μm to 90 μm, 20 μm to 85 μm, 20 μm to 80 μm, 20 μm to 75 μm, and 20 μm or less. The following are the minimum and maximum sizes: 71 μm or less, 40 μm to 110 μm, 40 μm to 100 μm, 40 μm to 90 μm, 40 μm to 85 μm, 40 μm to 80 μm, 40 μm to 75 μm, 40 μm to 71 μm, 50 μm to 110 μm, 50 μm to 100 μm, 50 μm to 90 μm, 50 μm to 85 μm, 50 μm to 80 μm, 50 μm to 71 μm, 54 μm to 110 μm, 54 μm to 100 μm, 54 μm to 90 μm, 54 μm to 85 μm, 54 μm to 80 μm, 54 μm to 75 μm, and 54 μm to 71 μm.

[0019] The arithmetic mean particle diameter and the arithmetic standard deviation of the particle diameter in the particle size distribution of the powder disclosed herein, calculated based on the number of particles, may be within a predetermined numerical range in order to enhance absorbency and solubility, suppress variations in product quality, control moisture absorption, and improve mixability. The above range of average particle diameter and the above range of standard deviation of particle diameter may be arbitrarily combined. For example, the average particle diameter may be 70 μm or more and 90 μm or less, and the standard deviation of particle diameter may be 50 μm or more and 75 μm or less. In another embodiment, for example, the average particle diameter is 230 μm or less and the standard deviation of particle diameter is 110 μm or less, 100 μm or less and the standard deviation of particle diameter is 100 μm or less, the average particle diameter is 100 μm or less and the standard deviation of particle diameter is 90 μm or less, the average particle diameter is 100 μm or less and the standard deviation of particle diameter is 85 μm or less, the average particle diameter is 100 μm or less and the standard deviation of particle diameter is 80 μm or less, the average particle diameter is 100 μm or less and the standard deviation of particle diameter is 75 μm or less, the average particle diameter is 90 μm or less and the standard deviation of particle diameter is 100 μm or less, the average particle diameter is 90 μm or less and the standard deviation of particle diameter is 90 μm or less, the average particle diameter is 90 μm or less and the standard deviation of particle diameter is 85 μm or less, and the average particle diameter is 90 μm or less and the standard deviation of particle diameter is 100 μm or less The difference may be 80 μm or less, the average particle diameter may be 90 μm or less and the standard deviation of particle diameter may be 75 μm or less, the average particle diameter may be 60 μm or more and 110 μm or less and the standard deviation of particle diameter may be 10 μm or more and 80 μm or less, the average particle diameter may be 65 μm or more and 100 μm or less and the standard deviation of particle diameter may be 10 μm or more and 80 μm or less, the average particle diameter may be 70 μm or more and 95 μm or less and the standard deviation of particle diameter may be 10 μm or more and 80 μm or less, the average particle diameter may be 70 μm or more and 93 μm or less and the standard deviation of particle diameter may be 10 μm or more and 80 μm or less, the average particle diameter may be 70 μm or more and 90 μm or less and the standard deviation of particle diameter may be 10 μm or more and 80 μm or less, the average particle diameter may be 72 μm or more and 88 μm or less and the standard deviation of particle diameter may be 54 μm or more and 71 μm or less, etc.

[0020] In the present disclosure, the average particle diameter refers to the average value of particle diameters determined on a number basis, and indicates the arithmetic average particle diameter calculated based on the number of particles in the particle size distribution for the particles contained in the powder (dry powder). The average particle diameter is calculated by treating all particles as a single particle and dividing the sum of the particle diameters by the number of particles. In the present disclosure, the average particle diameter is calculated by the following formula (I): Average particle diameter = Sum of particle diameters / Total number of particles ... (I) Further, in the present disclosure, the standard deviation of particle diameters is an arithmetic standard deviation, and is a value determined from the particle size distribution at the time of calculating the above average particle diameter. In addition, in the present disclosure, by calculating the particle diameter and its standard deviation on the basis of the number of particles, it is possible to evaluate the particle size distribution that appropriately reflects the presence of fine particles, and the uniformity of powder physical properties can be evaluated more accurately.

[0021] The particle diameter and its distribution (particle size distribution) are measured by a laser diffraction / scattering method. In one aspect, the particle size distribution in the present disclosure is obtained by the following measurement method, and the average particle diameter and the standard deviation of the particle diameters are determined based on this particle size distribution. ・Measurement method: Laser diffraction / scattering method Measurement apparatus: LS 13 320 (manufactured by Beckman Coulter, Inc.) Sample module: TORNADO Dry Powder System (manufactured by Beckman Coulter, Inc.) Dust collector: CV-G104C (manufactured by Hitachi, Ltd.) Measurement conditions: For the preparation of the sample powder, 4.6 g of the powder is weighed into a dedicated sample tube. The sample is dispersed with an ultrasonic cleaner and dried. The dried sample is dispersed with the TORNADO Dry Powder System, and measured with the LS 13 320 for 60 seconds. Analysis method: Analysis is performed based on the Fraunhofer diffraction theory to obtain a particle size distribution regarding the particle size and its frequency. The average particle diameter and the standard deviation of the particle diameters are determined from the obtained particle size distribution.

[0022] When the powders of this disclosure are prepared in multiple lots, the standard deviation of the average particle size between lots may be 100 μm or less, 50 μm or less, 30 μm or less, 20 μm or less, 15 μm or less, etc. In particular, the manufacturing method described later makes it possible to obtain powders with small variations in average particle size between lots. For example, even when mass-produced powders are sequentially placed into containers for storage and transport, the variation in average particle size due to the container can be reduced. A lower standard deviation of the average particle size between lots is preferable, and the lower limit should be 0 μm or more, but it may be 1.0 μm or more, 2.0 μm or more, 3.0 μm or more, etc. The range of the standard deviation of the average particle size between lots may be any combination of the lower and upper limits mentioned above.

[0023] In this specification, "lot" refers to a product unit in its shipping form. In this embodiment, for example, one lot refers to a form in which 10 kg of 5-aminolevulinic acid or its salt powder is filled into one fiber drum.

[0024] In this specification, when referring to the standard deviation between lots, it means the standard deviation based on the values ​​of all lots. However, an approximate value can usually be obtained by measuring two or more randomly selected lots, preferably five or more, more preferably seven or more, and even more preferably ten or more.

[0025] In the powder of the present disclosure, the ratio of the standard deviation of the average particle diameter between lots to the average particle diameter (standard deviation of average particle diameter / average particle diameter) is not particularly limited, but from the viewpoint of suppressing lot-to-lot variation and providing a powder of homogeneous quality, the upper limit value may be 0.4 or less, 0.3 or less, 0.2 or less, 0.15, 0.1 or less, etc., and the lower limit value may be 0 or more, 0.01 or more, 0.03 or more, 0.05 or more, etc. The above upper limit values and lower limit values may be arbitrarily combined, and for example, the ratio may be 0 to 0.4, 0 to 0.3, 0 to 0.2, 0 to 0.15, 0 to 0.1, 0.01 to 0.4, 0.01 to 0.3, 0.01 to 0.2, 0.01 to 0.15, 0.01 to 0.1, 0.03 to 0.4, 0.03 to 0.3, 0.03 to 0.2, 0.03 to 0.15, 0.03 to 0.1, 0.05 to 0.4, 0.05 to 0.3, 0.05 to 0.2, 0.05 to 0.15, 0.05 to 0.1, and the like.

[0026] In the present specification, the "bulk specific volume" is a value obtained by dividing the volume occupied by the powder by the mass when the powder is filled in a container and the mass thereof is measured. Specifically, it can be measured and calculated by the procedures shown in s1) to s4) described later. Crystals with a small bulk specific volume have excellent filling properties, are easy to handle in various processing steps, and have low transportation costs. Therefore, the powder containing 5-aminolevulinic acid or a salt thereof preferably has a small bulk specific volume.

[0027] The crude specific volume of the powder disclosed herein is not particularly limited, but is preferably 3.0 mL / g or less. This range allows the powder to have excellent packing properties, facilitate handling in various processing steps, and reduce transportation costs. The crude specific volume of the powder disclosed herein may be, for example, 2.9 mL / g or less, 2.8 mL / g or less, 2.7 mL / g or less, 2.6 mL / g or less, etc. The lower limit of the crude specific volume is not particularly limited, but may be 0.1 mL / g or more, 1.0 mL / g or more, 1.5 mL / g or more, 2.2 mL / g or more, etc. The above range of crude specific volume may be any combination of the above lower and upper limits. In another embodiment, the crude specific volume is 0.1 mL / g or more and 3.0 mL / g or less, 0.1 mL / g or more and 2.9 mL / g or less, 0.1 mL / g or more and 2.8 mL / g or less, 0.1 mL / g or more and 2.7 mL / g or less, 0.1 mL / g or more and 2.6 mL / g or less, 1.0 mL / g or more and 3.0 mL / g or less, 1.0 mL / g or more and 2.9 mL / g or less, 1.0 mL / g or more and 2.8 mL / g or less, 1.0 mL / g or more and 2.7 mL / g or less, and 1.0 mL / g or more and 2.6 mL / g or less, 1.5 mL / g or more and 3.0 mL / g or less, 1.5 mL / g or more and 2.9 mL / g or less, 1.5 mL / g or more and 2.8 mL / g or less, 1.5 mL / g or more and 2.7 mL / g or less, 1.5 mL / g or more and 2.6 mL / g or less, 2 .2 mL / g or more and 3.0 mL / g or less, 2.2 mL / g or more and 2.8 mL / g or less, 2.2 mL / g or more and 2.7 mL / g or less, or 2.3 mL / g or more and 2.6 mL / g or less.

[0028] When the powder of this disclosure is prepared in multiple lots, it is preferable that the lot-to-lot standard deviation of crude specific volume is 0.4 mL / g or less. The lot-to-lot standard deviation of crude specific volume may be 0.3 mL / g or less, 0.2 mL / g or less, 0.15 mL / g or less, 0.1 mL / g or less, etc. The lower limit of the lot-to-lot standard deviation of crude specific volume is not particularly limited, but it may be 0 mL / g or more, 0.01 mL / g or more, 0.02 mL / g or more, 0.03 mL / g or more, etc. In another embodiment, the lot-to-lot standard deviation of crude specific volume is 0 mL / g or more and 0.4 mL / g or less, 0 mL / g or more and 0.3 mL / g or less, 0 mL / g or more and 0.2 mL / g or less, 0 mL / g or more and 0.15 mL / g or less, 0 mL / g or more and 0.1 mL / g or less, 0.01 mL / g or more and 0.4 mL / g or less, 0.01 mL / g or more and 0.3 mL / g or less, 0.01 mL / g or more and 0.2 mL / g or less, 0.01 mL / g or more and 0.15 mL / g or less, and 0.01 mL / g or more and 0.1 mL / g. Below, 0.02 mL / g to 0.4 mL / g, 0.02 mL / g to 0.3 mL / g, 0.02 mL / g to 0.2 mL / g, 0.02 mL / g to 0.15 mL / g, 0.02 mL / g to 0.1 mL / g, 0 .03 mL / g or more and 0.4 mL / g or less, 0.03 mL / g or more and 0.2 mL / g or less, 0.03 mL / g or more and 0.15 mL / g or less, and 0.03 mL / g or more and 0.1 mL / g or less.

[0029] The powders of this disclosure are not particularly limited, but it is preferable that they have a crude specific volume of 3.0 mL / g or less and a lot-to-lot standard deviation of crude specific volume of 0.4 mL / g or less, or a crude specific volume of 2.6 mL / g or less and a lot-to-lot standard deviation of crude specific volume of 0.15 mL / g or less. In another embodiment, the crude specific volume may be 0.1 mL / g or more and 3.0 mL / g or less and the lot-to-lot standard deviation of the crude specific volume is 0 mL / g or more and 0.4 mL / g or less; the crude specific volume may be 0.1 mL / g or more and 3.0 mL / g or less and the lot-to-lot standard deviation of the crude specific volume is 0 mL / g or more and 0.4 mL / g or less; the crude specific volume may be 2.2 mL / g or more and 2.7 mL / g or less and the lot-to-lot standard deviation of the crude specific volume is 0.02 mL / g or more and 0.2 mL / g or less; the crude specific volume may be 2.3 mL / g or more and 2.6 mL / g or less and the lot-to-lot standard deviation of the crude specific volume is 0.02 mL / g or more and 0.2 mL / g or less; the crude specific volume may be 2.3 mL / g or more and 2.6 mL / g or less and the lot-to-lot standard deviation of the crude specific volume is 0.03 mL / g or more and 0.15 mL / g or less, and so on.

[0030] In this specification, "compressed specific volume" is the value obtained by dividing the volume occupied by the powder by the mass after filling a container with the powder and applying a certain impact. Specifically, it can be measured and calculated by the procedure shown in s1) to s4) below. Crystals with a small compressed specific volume have excellent packing properties, are easy to handle in various processing steps, and have low transportation costs. Therefore, it is preferable that powders containing 5-aminolevulinic acid or its salts have a small compressed specific volume.

[0031] The powder of this disclosure is not particularly limited, but preferably has a dense specific volume of 2.0 mL / g or less. This range allows the powder to have excellent packing properties, facilitate handling in various processing steps, and reduce transportation costs. The dense specific volume of the powder of this disclosure may be, for example, 1.7 mL / g or less, 1.5 mL / g or less, etc. The lower limit of the dense specific volume is not particularly limited, but may be 0.1 mL / g or more, 0.6 mL / g or more, 1.1 mL / g or more, 1.2 mL / g or more, etc. The above range of dense specific volume may be any combination of the above lower and upper limits. In another embodiment, the close-compression specific volume is, for example, 0.1 mL / g or more and 2.0 mL / g or less, 0.1 mL / g or more and 1.7 mL / g or less, 0.1 mL / g or more and 1.5 mL / g or less, 0.6 mL / g or more and 2.0 mL / g or less, 0.6 mL / g or more and 1.7 mL / g or less, 0.6 mL / g or more and 1.5 mL / g or less, 1.1 mL / g or more and 2.0 mL / g or less, 1.1 mL / g or more and 1.7 mL / g or less, 1.1 mL / g or more and 1.5 mL / g or less, 1.2 mL / g or more and 1.5 mL / g or less, and so on.

[0032] When the powder of this disclosure is prepared in multiple lots, it is preferable that the standard deviation of the dense specific volume between lots is 0.1 mL / g or less. The standard deviation of the dense specific volume between lots may be 0.08 mL / g or less, 0.07 mL / g or less, 0.06 mL / g or less, etc. The lower limit of the standard deviation of the dense specific volume between lots is not particularly limited, but it may be 0 mL / g or more, 0.01 mL / g or more, 0.015 mL / g or more, 0.02 mL / g or more, etc. In another embodiment, the lot-to-lot standard deviation of the dense specific volume is 0 mL / g or more and 0.1 mL / g or less, 0 mL / g or more and 0.08 mL / g or less, 0 mL / g or more and 0.07 mL / g or less, 0 mL / g or more and 0.06 mL / g or less, 0.01 mL / g or more and 0.1 mL / g or less, 0.01 mL / g or more and 0.08 mL / g or less, 0.01 mL / g or more and 0.07 mL / g or less, and 0.01 mL / g or more and 0.06 mL / g The following are examples: 0.015 mL / g or more and 0.1 mL / g or less, 0.015 mL / g or more and 0.08 mL / g or less, 0.015 mL / g or more and 0.07 mL / g or less, 0.015 mL / g or more and 0.06 mL / g or less, 0.02 mL / g or more and 0.1 mL / g or less, 0.02 mL / g or more and 0.08 mL / g or less, 0.02 mL / g or more and 0.07 mL / g or less, 0.02 mL / g or more and 0.06 mL / g or less, etc.

[0033] The powders of this disclosure are not particularly limited, but it is preferable that they have a dense specific volume of 2.0 mL / g or less and a lot-to-lot standard deviation of the dense specific volume of 0.1 mL / g or less, or a dense specific volume of 1.5 mL / g or less and a lot-to-lot standard deviation of the dense specific volume of 0.08 mL / g or less. In another embodiment, the specific volume may be 0.1 mL / g or more and 2.0 mL / g or less and the lot-to-lot standard deviation of the specific volume may be 0 mL / g or more and 0.1 mL / g or less; the specific volume may be 0.6 mL / g or more and 1.7 mL / g or less and the lot-to-lot standard deviation of the specific volume may be 0.01 mL / g or more and 0.08 mL / g or less; the specific volume may be 1.2 mL / g or more and 1.5 mL / g or less and the lot-to-lot standard deviation of the specific volume may be 0.01 mL / g or more and 0.08 mL / g or less; the specific volume may be 1.2 mL / g or more and 1.5 mL / g or less and the lot-to-lot standard deviation of the specific volume may be 0.015 mL / g or more and 0.07 mL / g or less; the specific volume may be 1.2 mL / g or more and 1.5 mL / g or less and the lot-to-lot standard deviation of the specific volume may be 0.02 mL / g or more and 0.06 mL / g or less.

[0034] Preferably, the powder of the present disclosure has an average particle diameter of 30 μm or more and 230 μm or less, a standard deviation of particle diameter of 0 μm or more and 110 μm or less, a crude specific volume of 0.1 mL / g or more and 3.0 mL / g or less, a lot-to-lot standard deviation of crude specific volume of 0 mL / g or more and 0.4 mL / g or less, a dense specific volume of 0.1 mL / g or more and 2.0 mL / g or less, and a lot-to-lot standard deviation of dense specific volume of 0 mL / g or more and 0.1 mL / g or less. More preferably, the powder of the present disclosure has an average particle diameter of 50 μm or more and 140 μm or less, a standard deviation of particle diameter of 40 μm or more and 90 μm or less, a crude specific volume of 0.1 mL / g or more and 3.0 mL / g or less, a lot-to-lot standard deviation of crude specific volume of 0 mL / g or more and 0.4 mL / g or less, a dense specific volume of 0.1 mL / g or more and 2.0 mL / g or less, and a lot-to-lot standard deviation of dense specific volume of 0 mL / g or more and 0.1 mL / g or less. More preferably, the powder of the present disclosure has an average particle diameter of 50 μm or more and 140 μm or less, a standard deviation of particle diameter of 40 μm or more and 90 μm or less, a crude specific volume of 1.5 mL / g or more and 2.8 mL / g or less, a lot-to-lot standard deviation of crude specific volume of 0.02 mL / g or more and 0.2 mL / g or less, a dense specific volume of 0.6 mL / g or more and 1.7 mL / g or less, and a lot-to-lot standard deviation of dense specific volume of 0.015 mL / g or more and 0.07 mL / g or less. Particularly preferably, the powder of the present disclosure has an average particle diameter of 70 μm or more and 90 μm or less, a standard deviation of particle diameter of 50 μm or more and 80 μm or less, a crude specific volume of 2.3 mL / g or more and 2.6 mL / g or less, a lot-to-lot standard deviation of crude specific volume of 0.03 mL / g or more and 0.1 mL / g or less, a dense specific volume of 1.2 mL / g or more and 1.5 mL / g or less, and a lot-to-lot standard deviation of dense specific volume of 0.02 mL / g or more and 0.06 mL / g or less.

[0035] To measure the crude and dense specific volumes of a powder, a method combining a general volumetric measuring device with a powder quantification and sampling technique is used. Specifically, first, an appropriate amount of powder sample is placed in a container and its mass is precisely measured. Next, the volume of the sample obtained is measured using a volumetric measuring device. Finally, the crude and dense specific volumes are calculated by dividing the measured volume by the mass of the sample.

[0036] In one aspect, the loose specific volume and the dense specific volume can be calculated by the procedures shown in s1) to s4) below. s1) Using an electronic balance, measure the tare mass W of a 50 mL glass graduated cylinder (inner diameter 20 mm) 0 . s2) A funnel is placed on the upper part of the graduated cylinder such that the end of the funnel tube is located 30 mm above the 50 mL graduation of the graduated cylinder. 5-Aminolevulinic acid or a salt thereof is introduced little by little into the graduated cylinder via the funnel until the 45 mL graduation of the graduated cylinder is reached. The mass W of 5-aminolevulinic acid or a salt thereof at the end of the introduction 1 is measured. The loose bulk density ABD is measured using the graduations of the graduated cylinder. The upper end H of the volume value indicated by 5-aminolevulinic acid or a salt thereof H1 and the lower end H L1 are measured, and ABD is calculated using the following formula (II). s3) Tapping was performed 75 times at a rate of 30 times / min with a drop of 20 mm, and the volume was measured. The packed bulk density PBD is measured using the graduations of the graduated cylinder. The upper end H of the volume value indicated by 5-aminolevulinic acid or a salt thereof H2 and the lower end H L2 are measured, and ABD is calculated using the following formula (III). s4) The loose specific volume and the dense specific volume are calculated using the following formulas (IV) and (V).

[0037] Loose bulk density ABD (mL) = (H H1 - H L1 ) / 2... Formula (II) Packed bulk density PBD (mL) = (H H2 - H L2 ) / 2... Formula (III) Loose specific volume (mL / g) = ABD / (W 1 - W 0 )... Formula (IV) Dense specific volume (mL / g) = PBD / (W 1 - W 0 )... Formula (V)

[0038] <Organic Solvent Contained in Powder> The powder may contain, as the organic solvent, at least one selected from, for example, ethanol, methanol, isopropanol, n-propanol, acetone, and acetonitrile. Typically, ethanol may be contained.

[0039] In the powder containing 5-aminolevulinic acid or a salt thereof according to this disclosure, the content of each organic solvent contained in one embodiment (the content of one type if one type is included, or the content of one type of each organic solvent if multiple types are included) is preferably 10,000 ppm by mass or less, preferably 3,000 ppm by mass or less, more preferably 1,000 ppm by mass or less, even more preferably less than 1,000 ppm by mass, even more preferably 750 ppm by mass or less, and particularly preferably 600 ppm by mass or less. The organic solvent content of the powder according to this disclosure is preferably as close to 0 ppm by mass as possible, but may be 10 ppm by mass or more, 20 ppm by mass or more, 30 ppm by mass or more, 90 ppm by mass or more, 160 ppm by mass or more, etc. The range of organic solvent content above may be any combination of the lower and upper limits above.In another embodiment, the content of the organic solvent is, for example, 0 mass ppm or more and 10,000 mass ppm or less, 0 mass ppm or more and 3,000 mass ppm or less, 0 mass ppm or more and 1,000 mass ppm or less, and 0 mass ppm or more and 100 mass ppm or less. Less than 0 mass ppm, 0 mass ppm or more and 750 mass ppm or less, 0 mass ppm or more and 600 mass ppm or less, 10 mass ppm or more and 10,000 mass ppm or less, 10 mass ppm or more and 3,000 mass ppm or less, 10 mass ppm or less 1000 mass ppm or less, 10 mass ppm or more and less than 1000 mass ppm, 10 mass ppm or more and 750 mass ppm or less, 10 mass ppm or more and 600 mass ppm or less, 20 mass ppm or more and 10000 mass ppm or less, 20 Mass ppm or more and 3000 mass ppm or less, 20 mass ppm or more and 1000 mass ppm or less, 20 mass ppm or more and less than 1000 mass ppm, 20 mass ppm or more and 750 mass ppm or less, 20 mass ppm or more and 600 mass ppm Below, 30 mass ppm or more and 10,000 mass ppm or less, 30 mass ppm or more and 3,000 mass ppm or less, 30 mass ppm or more and 1,000 mass ppm or less, 30 mass ppm or more and less than 1,000 mass ppm, 30 mass ppm or more 750 mass ppm or less, 30 mass ppm or more and 600 mass ppm or less, 90 mass ppm or more and 10,000 mass ppm or less, 90 mass ppm or more and 3,000 mass ppm or less, 90 mass ppm or more and 1,000 mass ppm or less, 90 quality The amounts may be ppm or more but less than 1,000 ppm by mass, 90 ppm or more but 750 ppm by mass or less, 90 ppm or more but 600 ppm by mass or less, 160 ppm or more but 10,000 ppm by mass or less, 160 ppm or more but 3,000 ppm by mass or less, 160 ppm or more but 1,000 ppm by mass or less, 160 ppm or more but less than 1,000 ppm by mass, 160 ppm or more but 750 ppm by mass or less, 160 ppm or more but 600 ppm by mass or less, etc. In this specification, "ppm by mass" means parts per million of mass.

[0040] The present inventors have found that in the production of a powder containing 5-aminolevulinic acid or a salt thereof, the content of each organic solvent, particularly the ethanol content, can be reduced to 1000 ppm by mass or less by pulverizing the crystals of 5-aminolevulinic acid or a salt thereof using impact pulverization.

[0041] The organic solvents contained in the powders of this disclosure mainly originate from organic solvents remaining after crystallization, and the amount of organic solvents contained in the powders of this disclosure may coincide with the amount of residual organic solvents. That is, examples of organic solvents that may be contained in the powders of this disclosure include organic solvents used in crystallization during the production of powders such as 5-aminolevulinic acid. In this disclosure, organic solvents remaining after crystallization are sometimes referred to as "residual organic solvents."

[0042] In the production of 5-aminolevulinic acid or its salts, crystallization using an organic solvent is often performed in the purification process. The organic solvent is used, for example, as a poor solvent. The 5-aminolevulinic acid or its salts prepared through crystallization may contain residual organic solvents from the crystallization process. Organic solvents are also difficult to remove from powders during crystal separation and drying processes in powder production. However, organic solvents such as ethanol remaining after the crystallization process reduce the purity of the product and adversely affect its stability.

[0043] Ethanol (EtOH) is an example of a poor solvent used for crystallization of 5-aminolevulinic acid. The Industrial Safety and Health Act established by the Ministry of Health, Labour and Welfare stipulates that if the ethanol concentration in a product is 1000 ppm by mass or more, it falls under the category of "hazardous and harmful substances that must be labeled or notified (substances subject to mandatory labeling and provision of safety data sheets)." However, when the inventors obtained three lots each of two commercially available 5-aminolevulinic acid powders and measured their ethanol content, they found that some lots contained residual ethanol exceeding the standard value of 1000 ppm by mass.

[0044] Labels and safety data sheets are intended to warn workers that they may be exposed to a significant amount of ethanol during dilution, mixing, or other operations when handling the labeled product. When handling labeled 5-aminolevulinic acid products, the purchaser will need to take measures to ensure occupational safety. Therefore, labeled 5-aminolevulinic acid products are more difficult to handle than unlabeled 5-aminolevulinic acid products, which may reduce customer willingness to purchase them.

[0045] On the other hand, the powder of one embodiment of the present disclosure has an ethanol content of less than 1,000 ppm by mass, and therefore the above-mentioned labeling is unnecessary.

[0046] In one embodiment, the powder containing 5-aminolevulinic acid or a salt thereof preferably has an ethanol content of 1,000 ppm by mass or less, more preferably less than 1,000 ppm by mass, even more preferably 750 ppm by mass or less, and even more preferably 600 ppm by mass or less. The ethanol content of the powder of this disclosure is preferably as close to 0 ppm by mass as possible, but may be 10 ppm by mass or more, 20 ppm by mass or more, 30 ppm by mass or more, 90 ppm by mass or more, 160 ppm by mass or more, etc. In another embodiment, the organic solvent content is, for example, 0 ppm or more and 1000 ppm or less, 0 ppm or more and less than 1000 ppm, 0 ppm or more and 750 ppm or less, 0 ppm or more and 600 ppm or less, 10 ppm or more and 1000 ppm or less, 10 ppm or more and less than 1000 ppm, 10 ppm or more and 750 ppm or less, 10 ppm or more and 600 ppm or less, 20 ppm or more and 1000 ppm or less, 20 ppm or more and less than 1000 ppm, 20 ppm or more and 750 ppm or less, 20 ppm or more and 600 ppm or less. The ethanol content may be less than or equal to 1000 ppm by mass, 30 ppm by mass or more but less than 1000 ppm by mass, 30 ppm by mass or more but less than 750 ppm by mass, 30 ppm by mass or more but less than 600 ppm by mass, 90 ppm by mass or more but less than 1000 ppm by mass, 90 ppm by mass or more but less than 750 ppm by mass, 90 ppm by mass or more but less than 600 ppm by mass, 160 ppm by mass or more but less than 1000 ppm by mass, 160 ppm by mass or more but less than 750 ppm by mass, 160 ppm by mass or more but less than 600 ppm by mass, etc. The above range of ethanol content may be any combination of the above lower and upper limits.

[0047] <Diffraction angles by powder X-ray diffraction> The powder of this disclosure preferably exhibits peaks at the diffraction angles 2θ of 7.9°±0.2°, 15.8°±0.2°, 18.9°±0.2°, 20.7°±0.2°, 21.1°±0.2°, 21.4°±0.2°, 22.9°±0.2°, 23.0°±0.2°, 27.8°±0.2°, and 33.2°±0.2° as diffraction angles 2θ by powder X-ray diffraction.

[0048] When the powder of this disclosure is a powder of 5-aminolevulinic acid phosphate, it is preferable that the powder exhibits peaks at diffraction angles 2θ of 7.9°±0.2°, 15.8°±0.2°, 18.9°±0.2°, 20.7°±0.2°, 21.1°±0.2°, 21.4°±0.2°, 22.9°±0.2°, 23.0°±0.2°, 27.8°±0.2°, and 33.2°±0.2° as diffraction angles 2θ determined by powder X-ray diffraction.

[0049] The ±0.2° in the peak value mentioned above is a measurement error due to measurement conditions such as the measuring instrument and peak reading conditions, and is preferably ±0.1°, more preferably ±0.01°. Powder X-ray diffraction can be performed according to the method described in the measurement example below.

[0050] (Example of powder X-ray diffraction measurement) Equipment used: Powder X-ray diffractometer (XRD) Ultima IV (manufactured by Rigaku Corporation) Anode: Cu Wavelength: 1.5418 Å Scanning range: 3.0 to 60.0° Scan speed: 10.0° / min Sampling width: 0.02° Voltage: 40 kV Current: 20 mA

[0051] <Melting Point> The powder of this disclosure preferably has a melting point of 129 to 131°C at 1 atmosphere. The melting point can be measured by the TG-DTA method.

[0052] <Content of 5-aminolevulinic acid or its salt> In the powder of the present disclosure, the content of 5-aminolevulinic acid or its salt per unit of solid content of the powder is preferably 99.5% by mass or more, and more preferably in the following order: 99.6% by mass or more, 99.7% by mass or more, 99.8% by mass or more, and 99.9% by mass or more.

[0053] In this disclosure, the content and amount of 5-aminolevulinic acid or its salts are calculated by, for example, in the case of 5-aminolevulinic acid phosphate, using a value obtained by converting 5-aminolevulinic acid (hereinafter also referred to as the free form) or its salt to the amount of 5-aminolevulinic acid phosphate in the same mole. In this disclosure, "content of 5-aminolevulinic acid or its salts" is synonymous with "purity of 5-aminolevulinic acid or its salts."

[0054] <Uses> The powder of this disclosure has uniform powder properties and can be preferably used as a raw material for products such as pharmaceuticals and supplements. Examples of pharmaceuticals include drugs for the treatment of infectious diseases, sterilization, diagnosis of hemophilus, hair removal, treatment of rheumatism, treatment of cancer, treatment of thrombosis, diagnosis of hair growth during cancer surgery, diagnosis of heavy metal poisoning porphyria, or prevention of anemia. Other uses of the powder of this disclosure include raw materials for derivative synthesis, animal cell culture, heme metabolism research, vitamin B12 production, heme enzyme production, microbial culture and porphyrin production in the microbiology field, or use in the agricultural field for regulating plant growth and improving salt tolerance, as well as other uses in the animal, food, or medical fields.

[0055] [2] Method for producing a powder containing 5-aminolevulinic acid or a salt thereof The method for producing the powder of the present disclosure (hereinafter also referred to as the method for producing the present disclosure) includes, in one embodiment, the following steps (1) and (2): (1) A step of preparing crystals of 5-aminolevulinic acid or a salt thereof (2) A step of grinding the crystals of 5-aminolevulinic acid or a salt thereof prepared in step (1) above by impact grinding. Each step will be described below.

[0056] <Steps for preparing 5-aminolevulinic acid or its salt crystals> Step (1) is a step for preparing 5-aminolevulinic acid or its salt crystals to be used in step (2). Commercially available 5-aminolevulinic acid or its salt crystals may be used as is, or 5-aminolevulinic acid or its salt crystals produced by known methods may be used. In one embodiment of step (1), steps (1A) to (1C) and (1E) below are included. (1A) A step of preparing a crystallization stock solution in which the concentration of 5-aminolevulinic acid or its salt is adjusted to a specific range by preparing a solution containing 5-aminolevulinic acid or its salt, and adding water to the solution or concentrating the solution. (1B) A step of adjusting the temperature of the crystallization stock solution obtained in (1A). (1C) A step of adding a first organic solvent to the crystallization stock solution obtained in (1B) to precipitate 5-aminolevulinic acid or its salt crystals. (1E) A step of separating the 5-aminolevulinic acid or its salt crystals.

[0057] 5-aminolevulinic acid is unstable at temperatures above 30°C and under neutral to basic conditions, and readily polymerizes to produce 2,5-pyrazinedipropanoic acid. In one embodiment of the manufacturing method of this disclosure, high-purity 5-aminolevulinic acid or its salt can be obtained by crystallization using an organic solvent.

[0058] The following describes each step (1A) to (1C). (1A) A step to prepare a crystallization stock solution in which the concentration of 5-aminolevulinic acid or its salt is adjusted to a specific range by preparing a solution containing 5-aminolevulinic acid or its salt, and adding water to the solution or concentrating the solution. Step (1A) is a step to prepare a crystallization stock solution in which the concentration of 5-aminolevulinic acid or its salt is adjusted to a specific range from a solution containing 5-aminolevulinic acid or its salt.

[0059] One embodiment of the manufacturing method of this disclosure does not include the steps of chemical synthesis and extraction of 5-aminolevulinic acid, and it is preferable that 5-aminolevulinic acid or its salt is a product derived from fermentation production. By not including the steps of chemical synthesis and extraction, the final crystals can be mass-produced inexpensively and in an environmentally friendly manner.

[0060] (Culture medium) In this specification, "culture medium" includes microorganisms, culture media, etc. The culture medium is obtained by culturing microorganisms capable of producing 5-aminolevulinic acid in a culture medium containing components necessary for their growth. Examples of microorganisms capable of producing 5-aminolevulinic acid (hereinafter also referred to as 5-aminolevulinic acid-producing bacteria) include recombinant microorganisms into which genes necessary for the production of 5-aminolevulinic acid have been introduced.

[0061] Examples of microorganisms include bacteria such as Escherichia coli, Lactobacillus lactis, Corynebacterium glutamicum, Bacillus subtilis, and Pseudomonas putita, or yeasts such as Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Pichia pastoris.

[0062] One method for genetically modifying microorganisms to produce 5-aminolevulinic acid is the method described in Japanese Patent Publication No. 2005-333907, which allows for the fermentation production of 5-aminolevulinic acid using recombinant Corynebacterium glutamicum.

[0063] The culture medium may contain a carbon source, a nitrogen source, a phosphorus source, a sulfur source, other organic components, other inorganic components, etc. The types, combinations, and amounts of these components in the culture medium may be set as appropriate. The culture medium may further contain amino acids, nucleic acids, vitamins, etc.

[0064] The carbon source is not particularly limited as long as it can be assimilated by the transformant, and examples include carbohydrates such as glucose, fructose, sucrose, glycerin, molasses, starch, and starch hydrolysates; organic acids such as gluconic acid, pyruvic acid, lactic acid, and acetic acid; and amino acids such as glycine, glutamic acid, alanine, and aspartic acid.

[0065] Examples of nitrogen sources include ammonia, ammonium chloride, ammonium sulfate, ammonium phosphate, ammonium nitrate, ammonium carbonate, ammonium acetate, and other various inorganic and organic ammonium salts; nitrogen-containing organic substances such as urea, peptone, NZ amine, meat extract, yeast extract, corn steep liquor, casein hydrolysate, fish meal or its digest, and various amino acids such as glycine and glutamic acid.

[0066] Examples of inorganic components include potassium dihydrogen phosphate, potassium monohydrogen phosphate, magnesium sulfate, magnesium phosphate, sodium chloride, ferrous sulfate, manganese sulfate, zinc sulfate, and calcium carbonate.

[0067] The presence of glycine in the culture medium is preferable because it improves the productivity of 5-aminolevulinic acid or its salt. The glycine content in the culture medium is preferably 0.5 to 20% by mass. Glycine may be added to the culture medium at any time, such as at the start of cultivation or during cultivation, and the required amount may be added all at once or in divided doses.

[0068] Furthermore, in the manufacturing method disclosed herein, it is not necessary to specifically add 5-aminolevulinic acid, which is generally added to the culture medium, etc., in the manufacturing method using microorganisms, but it may be added as needed.

[0069] It is preferable to remove various impurities added to the culture medium by a purification process. The solid components containing microorganisms can be separated from the culture medium, and the supernatant (solution A) containing 5-aminolevulinic acid can be recovered. Methods for separating the solid components containing microorganisms from the culture medium include centrifugation and filtration.

[0070] Solution A can be passed through a column packed with ion exchange resin or the like to remove water-soluble impurities and salts and obtain solution B. If solution B contains impurities that hinder crystallization, it can be passed through a column packed with ion exchange resin, synthetic adsorption resin, activated carbon, etc., or by adding such materials, and then filtered to remove the impurities and salts and obtain solution C.

[0071] The pH of solution B or solution C is preferably 0.5 to 7.0, more preferably 2.0 to 4.0, and most preferably 2.5 to 3.0. Examples of pH adjusting agents for adjusting this pH include hydrochloric acid, sulfuric acid, phosphoric acid, phosphorous acid, nitric acid, nitrite, acetic acid, potassium hydroxide, sodium hydroxide, sodium carbonate, potassium carbonate, and ammonia, with phosphoric acid and hydrochloric acid being preferred, and phosphoric acid being the most preferred. Two or more of these pH adjusting agents may be used in mixture form.

[0072] Solution B or Solution C obtained in the above process can be concentrated to obtain Solution D by a general concentration method such as a heating concentration method or a vacuum concentration method. The content of 5-aminolevulinic acid or its salt in Solution D is preferably 10 to 900 g / L, more preferably 50 to 800 g / L, even more preferably 100 to 700 g / L, and most preferably 200 to 700 g / L.

[0073] (Filtration) One method of filtration is to perform microfiltration of solution D using a membrane with a diameter of 0.2 to 1.2 μm. Specifically, one method is to treat solution D or a solution obtained by treating solution D with activated carbon using a membrane filter.

[0074] (Decolorization) Activated carbon may be added to decolorize solution D to obtain solution E. Examples of activated carbon include Carborafin (registered trademark), Kyoryoku Shirasagi (hereinafter, Shirasagi is a registered trademark), Purified Shirasagi, Special Shirasagi, Shirasagi A, Shirasagi C, Shirasagi ANOX-1, Shirasagi FAC-10, Shirasagi WP-H, Shirasagi DO-2, Shirasagi DO-5, Granular Shirasagi G2c, Granular Shirasagi WH2c, Granular Shirasagi W2c, Granular Shirasagi WH5c, Granular Shirasagi W5c, Granular Shirasagi LGK-100, Granular Shirasagi LGK-400, Granular Shirasagi KL, Granular Shirasagi LH2c, Spherical Shirasagi X8100H, Spherical Shirasagi XS8100H, and Granular Shirasagi G, all manufactured by Osaka Gas Chemical Co., Ltd. 2x, Granular Shirasagi G5x, Granular Shirasagi S2x, Granular Shirasagi WH2x, Granular Shirasagi X2M, Granular Shirasagi C2c, Granular Shirasagi C2x, Spherical Shirasagi X7000H, spherical white heron X7100H, spherical white heron XS7100H, spherical white heron X7000H-3, spherical white heron Examples include Spherical Shirasagi LGK-700, Spherical Shirasagi DX7-3, Shirasagi M, Shirasagi P, Granular Shirasagi GM2X, Seitz AKSJ, and Taiko (hereinafter, Taiko is a registered trademark) S, Taiko K, Taiko P, Taiko W, Taiko A, and Taiko Y manufactured by Futamura Chemical Co., Ltd., with Taiko S being preferred.

[0075] Solution D or solution E may be passed through a chelate resin to obtain solution F. Examples of chelate resins include those having a sulfone group, iminodiacetic acid, or aminomethylphosphonic acid as an exchange group, and whose resin matrix is ​​porous, macroporous, gel, styrene, or acrylic.

[0076] Examples of chelate resins include DuPont's C467, Purolite's MTS9500, and LANXESS's Lewatit® CNP80, CNP80WS, MDSTP208, MDSTP260, TP207, TP208, TP209XL, and TP260.

[0077] Furthermore, the solutions D, E, or F obtained in the above process may be subjected to ultrafiltration by passing them through an ultrafiltration membrane (hereinafter also referred to as "UF membrane") (MWCO = 6000) capable of removing substances with a molecular weight of 6000 or more, to obtain solution G by removing, for example, endotoxins, proteins, high molecular weight peptides, toxins, etc. from the decolorized filtrate. Furthermore, microfiltration can be performed before or after this process using a membrane with a diameter of 0.2 to 1.2 μm. Specifically, for example, a method using a membrane filter can be used.

[0078] The solutions D, E, F, or G obtained in the above process can be concentrated by general concentration methods such as heating concentration, membrane concentration, or vacuum concentration, or filtered to obtain a crystallization stock solution containing 5-aminolevulinic acid or a salt thereof. The concentration of the crystallization stock solution is not particularly limited, but it is preferably 200 to 700 g / L.

[0079] (Preparation of crystallization stock solution) For solutions D, E, F, or G obtained in the above step, a crystallization stock solution containing 5-aminolevulinic acid or its salt can be obtained by general concentration methods such as diluting an aqueous solution of 5-aminolevulinic acid or its salt with water, heating and concentrating, membrane concentration, or vacuum concentration.

[0080] The concentration of 5-aminolevulinic acid or its salt in the crystallization stock solution is preferably 700 g / L or less, 650 g / L or less, and 600 g / L or less in terms of 5-aminolevulinic acid phosphate, and preferably 200 g / L or more, 260 g / L or more, 300 g / L or more, 400 g / L or more, and 500 g / L or more in terms of 5-aminolevulinic acid phosphate. These upper and lower limits can be combined arbitrarily. In another embodiment, the concentration of 5-aminolevulinic acid or its salt in the crystallization stock solution is preferably 200 to 700 g / L, more preferably 260 to 650 g / L, 260 to 600 g / L, 300 to 700 g / L, even more preferably 400 to 700 g / L, and most preferably 500 to 650 g / L in terms of 5-aminolevulinic acid phosphate. By setting the concentration of 5-aminolevulinic acid or its salt in the crystallization stock solution within the above range, residual organic solvents can be reduced, thereby improving product quality.

[0081] To achieve the above concentration of 5-aminolevulinic acid or its salt in an aqueous solution, it may be dissolved using deionized water or the like. Alternatively, the aqueous solution containing 5-aminolevulinic acid or its salt can be concentrated and prepared using general concentration methods such as heating concentration or vacuum concentration.

[0082] Step (1B) is a step to adjust the temperature of the crystallization stock obtained in step (1A). Step (1B) is a step to adjust the temperature of the crystallization stock obtained in step (1A) to a specific range. Preferably, the temperature of the crystallization stock is 30°C or lower, 25°C or lower, or 20°C or lower, and preferably 5°C or higher. These upper and lower limits can be combined arbitrarily. In another embodiment, the temperature of the crystallization stock is preferably 5 to 30°C, more preferably 5 to 25°C, even more preferably 5 to 20°C, and most preferably 10 to 20°C. By setting the temperature of the crystallization stock within the above range, residual organic solvents can be further reduced and product quality can be improved. Examples of methods for adjusting the temperature of the crystallization stock include a constant temperature bath, a jacketed tank, etc.

[0083] Step (1C) is a step in which a first organic solvent is added to the crystallization stock solution obtained in (1C) and (1B) to precipitate crystals of 5-aminolevulinic acid or its salt.

[0084] In step (1C), the amount of the first organic solvent added is 0.55 v / v or less, preferably 0.50 v / v or less, more preferably 0.45 v / v or less, and even more preferably 0.40 v / v or less, relative to the volume of the crystallization stock solution. The lower limit of the amount of the first organic solvent added is not particularly limited, but is 0.01 v / v or more, relative to the volume of the crystallization stock solution. These upper and lower limits can be combined arbitrarily. In another embodiment, the amount of the first organic solvent added is 0.01 to 0.55 v / v, 0.01 to 0.50 v / v, 0.01 to 0.45 v / v, or 0.01 to 0.40 v / v, relative to the volume of the crystallization stock solution.

[0085] In the step of adding the first organic solvent, the crystallization temperature is not particularly limited, but it is preferably the same temperature as in step (1B). In step (1C), the rate at which the organic solvent is added is not particularly limited, as long as there is no precipitation of solid due to a local decrease in solubility.

[0086] (First Organic Solvent) In step (1C), the first organic solvent is preferably at least one organic solvent selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, acetone, acetonitrile, 1-propanol, 2-propanol, ethyl acetate, 1-butanol, 2-butanol, heptane, isopropyl acetate, methyl ethyl ketone, propyl acetate, and tetrahydrofuran. Among these, at least one organic solvent selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, acetone, acetonitrile, 1-propanol, and 2-propanol is more preferred, and most preferably ethanol. Furthermore, these organic solvents may be used individually or in combination of multiple types.

[0087] In step (1C), the first organic solvent may be added as a mixture with an organic solvent, a mixture with water, or a mixture of an organic solvent and water. The concentration of the first organic solvent in the mixture is preferably 30% by volume or more, more preferably 50% by volume or more, even more preferably 80% by volume or more, and most preferably 100% by volume. These upper and lower limits can be combined arbitrarily. In another embodiment, the concentration of the first organic solvent in the above mixture is preferably 30 to 100% by volume, more preferably 50 to 100% by volume, and even more preferably 80 to 100% by volume.

[0088] (Seed crystals) In step (1C), seed crystals may be added to the crystallization stock before the crystals of 5-aminolevulinic acid or its salt precipitate. The timing of adding the seed crystals to the crystallization stock is not particularly limited, but from the viewpoint of purification efficiency, for example, it is preferably within 0 to 12 hours, more preferably within 0 to 8 hours, even more preferably within 0 to 4 hours, and most preferably immediately after the end of the addition of the first organic solvent, from the start of the addition of the first organic solvent.

[0089] The amount of seed crystal added to the crystallization stock solution is preferably 0.01 to 5.0% by mass, more preferably 0.01 to 3.0% by mass, even more preferably 0.01 to 0.5% by mass, and most preferably 0.05 to 0.5% by mass, relative to 5-aminolevulinic acid or its salt in the crystallization stock solution. By setting the amount of seed crystal added within the above range, residual organic solvent can be further reduced and product quality can be improved.

[0090] After adding the seed crystals, it is preferable that the entire crystallization stock solution containing the seed crystals is stirred in a nearly uniform state, and that the mixture be allowed to mature so that the added seed crystals can grow. The main purpose of maturation is to grow and increase the size of the crystals, but the precipitation of new crystals may occur simultaneously with the growth of the crystals.

[0091] The crystal maturation time, measured starting from the completion of seed crystal addition, is preferably less than 360 minutes and 240 minutes or less, and preferably 1 minute or more and 10 minutes or more. These upper and lower limits can be combined arbitrarily. In another embodiment, the crystal maturation time, measured starting from the completion of seed crystal addition, is preferably 1 to 359 minutes, more preferably 1 to 240 minutes, even more preferably 10 to 359 minutes, and most preferably 10 to 240 minutes. By setting the crystal maturation time within the above range, residual organic solvents can be further reduced and product quality can be improved.

[0092] The temperature at which the seed crystal is added to the crystallization stock solution is not particularly limited as long as the seed crystal does not dissolve, but it is preferably 30°C or lower, 25°C or lower, 20°C or lower, and preferably 5°C or higher. These upper and lower limits can be combined arbitrarily. In another embodiment, the temperature at which the above seed crystal is added to the crystallization stock solution is preferably 5 to 30°C, more preferably 5 to 25°C, and even more preferably 15 to 20°C.

[0093] (1D) Step of adding a second organic solvent to the crystallization stock solution The manufacturing method of the present disclosure preferably includes a step (1D) of adding a second organic solvent to the crystallization stock solution after adding the seed crystal to the crystallization stock solution in step (1C). One or more of the organic solvents listed as the first organic solvent can be used as the second organic solvent. The timing of adding the second organic solvent to the crystallization stock solution is not particularly limited, but from the viewpoint of purification efficiency, for example, immediately after the crystal ripening is completed is preferred.

[0094] The amount of the second organic solvent added is preferably 3.0 v / v or less, more preferably 2.6 v / v or less, even more preferably 2.4 v / v or less, and most preferably 2.0 v / v or less, relative to the volume of the crystallization stock solution. The lower limit of the amount of the second organic solvent added is not particularly limited, but it is preferably 0.1 v / v or more, relative to the volume of the crystallization stock solution. These upper and lower limits can be combined arbitrarily. In another embodiment, the amount of the second organic solvent added is preferably 0.1 to 3.0 v / v, more preferably 0.1 to 2.5 v / v, even more preferably 0.1 to 2.2 v / v, and most preferably 0.1 to 2.0 v / v, relative to the volume of the crystallization stock solution.

[0095] The total amount of the first and second organic solvents added to the crystallization stock solution is preferably 3.0 v / v or less, more preferably 2.5 v / v or less, even more preferably 2.2 v / v or less, and most preferably 2.0 v / v or less, relative to the volume of the crystallization stock solution. The amount of the first and second organic solvents added is not particularly limited to the lower limit of the volume of the crystallization stock solution, but is preferably 0.1 v / v or more. These upper and lower limits can be combined arbitrarily. In another embodiment, the amount of the first and second organic solvents added is preferably 0.1 to 3.0 v / v, more preferably 0.1 to 2.5 v / v, even more preferably 0.1 to 2.2 v / v, and most preferably 0.1 to 2.0 v / v, relative to the volume of the crystallization stock solution.

[0096] In step (1D), the crystallization temperature is not particularly limited, but it is preferably the same temperature as in step (1B). The rate at which the second organic solvent is added to the crystallization stock is not particularly limited as long as there is no precipitation of solids due to a decrease in local solubility, but it is preferably 5.0 v / v / h or less, 2.0 v / v / h or less, 1.5 v / v / h or less, or 1.0 v / v / h or less relative to the volume of the crystallization stock. The rate at which the second organic solvent is added to the crystallization stock is not particularly limited in terms of the lower limit, but it is preferably 0.1 v / v or more relative to the volume of the crystallization stock. These upper and lower limits can be combined arbitrarily. In another embodiment, the rate at which the second organic solvent is added to the crystallization stock is preferably 0.4 to 5.0 v / v / h, more preferably 0.4 to 2.0 v / v / h, even more preferably 0.4 to 1.5 v / v / h, and most preferably 0.4 to 1.0 v / v / h relative to the volume of the crystallization stock.

[0097] In step (1D), the second organic solvent may be added as a mixture with an organic solvent, a mixture with water, or a mixture of an organic solvent and water. The concentration of the second organic solvent in the mixture is preferably 30% by volume or more, more preferably 50% by volume or more, even more preferably 80% by volume or more, and most preferably 100% by volume. These upper and lower limits can be combined arbitrarily. In another embodiment, the concentration of the second organic solvent in the above mixture is preferably 30 to 100% by volume, more preferably 50 to 100% by volume, and even more preferably 80 to 100% by volume.

[0098] (1E) Step to separate the crystals The manufacturing method of the present disclosure preferably further includes a step to separate the crystals from the crystallization stock solution. For example, a method for removing the organic solvent from the crystals obtained by the above crystallization is crystal separation and drying.

[0099] (Crystal Separation) The method for separating the crystals is not particularly limited as long as the crystals and mother liquor can be separated, but examples include filtration, pressure filtration, suction filtration, and centrifugation. In the case of centrifugation, it is preferable to wash the crystals from the viewpoint of removing impurities. For example, the crystals can be washed using an organic solvent added during crystallization or an aqueous solution containing an organic solvent.

[0100] The amount of crystal washing solution used for crystal washing is preferably 0.5 to 2 v / w, more preferably 0.9 to 1.1 v / w, and even more preferably 0.9 to 1.0 v / w, in volume ratio to the mass of 5-aminolevulinic acid crystals.

[0101] (Drying) The drying method is not particularly limited as long as it can remove the organic solvent, prevent the decomposition of 5-aminolevulinic acid, and maintain the crystalline form. For example, vacuum drying, fluidized bed drying, and forced-air drying can be applied. The remaining organic solvent will also be removed in the subsequent step of crushing the crystals, but it is preferable to reduce the content as much as possible at this stage (for example, to 10,000 ppm by mass or less).

[0102] The drying temperature is not particularly limited as long as it can remove any adhering moisture and solvent, but is preferably 50°C or lower, more preferably 40°C or lower, and most preferably 30°C or lower. The lower limit of the drying temperature is not particularly limited, but is preferably 4°C or higher. These upper and lower limits can be combined arbitrarily. In another embodiment, the drying temperature is preferably 4 to 50°C, more preferably 4 to 40°C, and even more preferably 4 to 30°C.

[0103] The drying time is not particularly limited as long as it can remove any adhering moisture and solvent, but is generally 48 hours or less, 24 hours or less, 10 hours or less, or 5 hours or less. The lower limit is not particularly limited, but is 1 hour or more. These upper and lower limits can be combined arbitrarily. In another embodiment, the drying time is preferably 1 to 48 hours, more preferably 1 to 24 hours, even more preferably 1 to 10 hours, and most preferably 1 to 5 hours.

[0104] Furthermore, in the case of vacuum drying, the pressure is not particularly limited, but from the viewpoint of purification efficiency, it is preferable to have a pressure of 0.1 hPa or higher, 1 hPa or higher, or 10 hPa or higher. As for the pressure of vacuum drying, there is no particular upper limit, but it is preferable to have a pressure of 150 hPa or lower, 100 hPa or lower, or 80 hPa or lower. These upper and lower limits can be arbitrarily combined. In another embodiment, the pressure of vacuum drying is preferably 0.1 to 150 hPa, more preferably 1 to 100 hPa, and even more preferably 10 to 80 hPa.

[0105] <Step of grinding 5-aminolevulinic acid or its salt crystals by impact grinding> In one embodiment, the manufacturing method of the present disclosure includes a step of grinding 5-aminolevulinic acid or its salt crystals by impact grinding. In particular, it includes a step (2) of grinding the 5-aminolevulinic acid or its salt crystals prepared in step (1) by impact grinding. The manufacturing method of the present disclosure including this step makes it possible to obtain a powder containing 5-aminolevulinic acid or its salt having uniform powder properties without including, for example, an additional step for sorting the powder by particle size. In this specification, "impact grinding" means applying an external force to a crystal to generate a shear force, compressive force or peeling force inside the crystal, thereby applying a mechanical impact and grinding it. In one embodiment, impact grinding includes grinding by at least one type of impact selected from piercing impact, crushing impact and shearing impact.

[0106] Examples of impact-type grinding include i) grinding using a high-speed airflow, and ii) grinding by collision or friction with a high-speed rotating grinding medium, or a combination thereof. In one embodiment of i) grinding using a high-speed airflow, grinding by a jet mill is used. A jet mill works by using a high-pressure gas (usually air or nitrogen) to collide with particles in the grinding chamber at high speed, and the particles are finely ground by the impact.

[0107] i) In the grinding method using high-speed airflow described above, impurities may be introduced depending on the purity of the gas, the interaction between the gas and the crystals, and the environment inside the apparatus. Furthermore, the gas used in this process may be subject to regulations under the Food Sanitation Law and the Food Labeling Law. Therefore, from the viewpoint of improving product quality, ii) grinding by collision or friction with a high-speed rotating grinding medium, or a combination thereof, is preferable to i) grinding using high-speed airflow.

[0108] ii) In the above, grinding by collision or friction with a high-speed rotating grinding medium, or a combination thereof, the grinding medium can be, for example, a ball, a pin, a bead, or a hammer. In one embodiment, the grinding includes grinding using a mortar and pestle and grinding using a high-speed rotary grinder. In one embodiment, the high-speed rotary grinder is preferably a fine grinder (capable of grinding to an average particle size of about 100 μm to 1 μm). Examples of high-speed rotary grinders that are fine grinders include a pin mill or a hammer mill, with a pin mill being preferred.

[0109] As a condition for impact pulverization, in one embodiment, from the viewpoint of further reducing residual solvent, the lower limit of the powder supply speed for supplying powder to the pulverizer is not particularly limited, but it is preferably 1 kg / h or more, more preferably 50 kg / h or more, and also preferably 2700 kg / h or less, more preferably 1000 kg / h or less, and even more preferably 250 kg / h or less.

[0110] In one embodiment, as a condition for impact pulverization, from the viewpoint of making the powder properties more uniform and further reducing residual solvent, the lower limit of the frequency in pulverization is not particularly limited, but it is preferably 1 to 60 Hz, which is the operating rotational speed of the pulverizer, more preferably 40 Hz or higher, and even more preferably 45 Hz or higher.

[0111] The form of the 5-aminolevulinic acid or its salt crystals subjected to grinding is not particularly limited, but in one embodiment, it may be in powder form. In one embodiment, from the viewpoint of making the powder properties more uniform and further reducing residual solvent, the average particle size of the powder crystals of 5-aminolevulinic acid or its salt subjected to grinding is 650 μm or less, 500 μm or less, 350 μm or less, 300 μm or less, etc. Alternatively, it may be greater than 230 μm, 240 μm or more, 250 μm or more, etc. The above range of average particle size may be any combination of the above lower and upper limits. Furthermore, there may be variation in the particle size of the powder crystals of 5-aminolevulinic acid or its salt subjected to grinding, and the standard deviation is not limited. For example, it may be greater than 110 μm, 120 μm or more, 200 μm or more, etc. Through this process, a powder with uniform powder properties can be obtained from crystals with varying particle sizes. On the other hand, in one embodiment, the crystals to be ground may have a standard deviation of more than 400 μm and 300 μm or less.

[0112] In one embodiment, the grinding temperature is not particularly limited, but is preferably 20 to 25°C. In one embodiment, the grinding atmosphere is not particularly limited, but is preferably air.

[0113] <Other steps> The manufacturing method of the present disclosure may include steps other than those described in (1) and (2) above. For example, it may further include a step of separating by particle size (such as a sieving step).

[0114] The powder containing 5-aminolevulinic acid or a salt thereof obtained by the powder manufacturing method of this disclosure can be filled into containers for post-manufacturing storage or transport. The powder obtained by the powder manufacturing method of this disclosure can be mass-produced, for example, in units of 100 kg to several hundred tons, and even when the powder is filled into multiple containers, the variation in average particle size between containers is small.

[0115] As described above, the following configurations are disclosed in this specification: <1> A powder containing 5-aminolevulinic acid or a salt thereof, wherein the average particle diameter calculated based on the number of particles in the particle size distribution is 230 μm or less, and the standard deviation of the particle diameter in the particle size distribution is 110 μm or less. <2> The powder according to <1>, wherein the crude specific volume is 3.0 mL / g or less. <3> The powder according to <1> or <2>, wherein the dense specific volume is 2.0 mL / g or less. <4> The powder according to any one of <1> to <3>, wherein the content of each organic solvent is 1000 ppm by mass or less. <5> The powder according to <4>, wherein the organic solvent is at least one selected from ethanol, methanol, isopropanol, n-propanol, acetone, and acetonitrile. <6> The powder according to any one of <1> to <5>, wherein the ethanol content is less than 1000 ppm by mass. <7> A method for producing a powder containing 5-aminolevulinic acid or a salt thereof, comprising the following steps (1) and (2): (1) a step of preparing crystals of 5-aminolevulinic acid or a salt thereof; (2) a step of grinding the crystals of 5-aminolevulinic acid or a salt thereof prepared in step (1) by impact grinding. <8> The method according to <7>, wherein the impact grinding is grinding by a high-speed rotary grinder. <9> The method according to <8>, wherein the high-speed rotary grinder is a fine grinder. <10> The method according to <9>, wherein the fine grinder is a pin mill. <11> The method according to any one of <7> to <10>, wherein the average particle diameter calculated based on the number of particles in the particle size distribution of the powder is 230 μm or less and the standard deviation of the particle diameter in the particle size distribution is 110 μm or less. <12> The method according to any one of <7> to <11>, wherein the crude specific volume of the powder is 3.0 mL / g. <13> The manufacturing method according to any one of <7> to <12>, wherein the dense specific volume of the powder is 2.0 mL / g. <14> The manufacturing method according to any one of <7> to <13>, wherein step (1) above includes crystallization using an organic solvent, and the content of each of the organic solvents remaining in the powder is less than 1000 ppm by mass.<15> The manufacturing method according to <14>, wherein the organic solvent is at least one selected from methanol, ethanol, isopropanol, n-propanol, acetone, and acetonitrile.

[0116] The present disclosure will be described below using examples, but the present disclosure is not limited to these examples. Unless otherwise specified, % refers to mass % and ppm refers to mass ppm.

[0117] [Procedures for various analytical methods] <Gas chromatography (GC)> (Analysis example 1: Measurement of ethanol content in 5-aminolevulinic acid phosphate powder) Standard ethanol solutions at 0.008 g / L, 0.016 g / L, 0.040 g / L, 0.080 g / L, and 0.160 g / L, and sample solutions were prepared with deionized water so that the concentration of 5-aminolevulinic acid phosphate was 50 g / L. Analysis was performed under the following conditions, and the ethanol peak (retention time: 1.6 minutes) was detected. The ethanol was quantified from the peak area value of the standard using the five-point check curve method.

[0118] GC Analysis Conditions Equipment: GC-2014 (Shimadzu Corporation) Hydrogen Generator: HE-260 (Shimadzu Corporation) Autosampler: AOC-20s (Shimadzu Corporation) Separation Column: DB-WAX (30m x 0.530mm x 1.0μm, Agilent) Carrier Gas: Helium Carrier Gas Flow Rate: 25.0 mL / min Sample Introduction Volume: 1.0 μL Column Temperature: 35.0°C Vaporization Chamber Temperature: 200°C Detector Temperature: 230.0°C Detector: Flame Ionization Detector (FID)

[0119] (Calculation of ethanol content in 5-aminolevulinic acid phosphate powder) The residual ethanol value of 5-aminolevulinic acid phosphate powder was calculated based on the calibration curve Y = AX + B obtained from the above ethanol standard solutions of 0.008 to 0.160 g / L.

[0120] The X-axis represents the concentration of the ethanol standard solution, and the Y-axis represents the peak area value detected from each ethanol standard solution. The slope of the calibration curve is A, the intercept is B, the peak area value of the ethanol in the sample solution is C, and the weighed value of the 5-aminolevulinic acid phosphate powder is W. 1(g) and the volume of the 5-aminolevulinic acid phosphate solution is L 1 (L) The concentration of ethanol in the sample solution was calculated using the following formula (I).

[0121] Ethanol content (ppm) = (C - B) / A / W 1 ×L 1 ×1,000,000… Equation (I)

[0122] <Laser Diffraction and Scattering Method: Particle Size and Size Distribution Measurement Device> (Analysis Example 2: Measurement of Particle Size Distribution of 5-Aminolevulinic Acid Phosphate Powder) 4.6 g of 5-aminolevulinic acid phosphate powder was weighed into a dedicated sample tube (REF383250, manufactured by Beckman Coulter, Inc.). The particle size distribution of the sample powder was measured using a particle size distribution measurement device.

[0123] Particle size distribution analyzer analysis conditions Equipment used: LS 13 320 (Beckman Coulter, Inc.) Sample module: TORNADO Dry Powder System (Beckman Coulter, Inc.) Dust collector: CV-G104C (Hitachi, Ltd.) Measurement time: 60 seconds

[0124] Procedure for measuring particle size (particle size distribution): 1) The sample was dispersed using an ultrasonic cleaner (40 kHz, 10 minutes) and then dried. 2) The dried sample was uniformly dispersed using the TORNADO Dry Powder System. 3) The dispersed powder was measured for 60 seconds using an LS 13 320. 4) The particle size distribution data obtained from the measurement results was analyzed to determine the average particle size and the standard deviation of the particle size.

[0125] <Specific Volume Measurement> (Analysis Example 3: Specific Volume Measurement of 5-Aminolevulinic Acid Phosphate Powder) The specific volume of 5-aminolevulinic acid phosphate powder was measured according to the procedure shown in s1) to s4) below. s1) Using an electronic balance, the tare mass W of a 50 mL glass graduated cylinder (inner diameter 20 mm) was measured. 0The following was measured: s2) The funnel was placed on top of the graduated cylinder so that the end of the funnel tube was 30 mm from the 50 mL mark on the graduated cylinder, and 5-aminolevulinic acid or its salt was added to the graduated cylinder little by little through the funnel until it reached the 45 mL mark on the graduated cylinder. The mass W of the 5-aminolevulinic acid phosphate powder at the end of the addition was measured. 1 The following was measured. The loosened volume ABD was measured using the scale of a graduated cylinder. Because the 5-aminolevulinic acid phosphate powder in the graduated cylinder is not flat, the upper limit H of the volume value indicated by the 5-aminolevulinic acid phosphate powder was measured. H1 and lower end H L1 The volume was measured and ABD was calculated using the following formula (II). s3) The volume was measured by tapping 75 times at 30 taps / min over a drop of 20 mm. The firmness PBD was measured using the scale of a graduated cylinder. Because the 5-aminolevulinic acid phosphate powder in the graduated cylinder is not flat, the upper limit H of the volume value indicated by the 5-aminolevulinic acid phosphate powder was used. H2 and lower end H L2 The following measurements were taken, and ABD was calculated using the following formula (III). 4) The crude specific volume and dense specific volume were calculated using the following formulas (IV) and (V).

[0126] Looseness ABD (mL) = (H H1 -H L1 ) / 2...Equation (II) Firmness PBD (mL) = (H H2 -H L2 ) / 2...Formula (III) Crude specific volume (mL / g)=ABD / (W 1 -W 0 )...Formula (IV) Dense specific volume (mL / g) = PBD / (W 1 -W 0 )...Formula (V)

[0127] [Preparation Example 1: Production of Powder with High Content of 5-Aminolevulinic Acid Phosphate (Coarse Formulation)] (1A) Preparation Process of Crystallization Stock Solution (Step 0) Fermentation production of 5-aminolevulinic acid was carried out using recombinant Corynebacterium glutamicum according to the method described in Japanese Patent Publication No. 2005-333907, and then sulfuric acid was added to adjust the pH to 3.0 ± 0.2. Subsequently, the culture broth was maintained at 20 ± 10°C for 5 hours or more to inactivate the 5-aminolevulinic acid producing bacteria and obtain a culture solution of 58.7 kL containing 34.7 g / L of 5-aminolevulinic acid.

[0128] Inactivated microbial cells were separated from the fermentation broth using a cross-flow filter (0.1 μm filter) to obtain 147.7 kL of a solution (referred to as Solution A) containing 14.0 g / L of 5-aminolevulinic acid.

[0129] As Preparation Example 1, the prepared solution A was subjected to ion exchange chromatography in the following first, second, and third steps.

[0130] In this disclosure, the amount of solution passing through the ion exchange resin is expressed as resin volume (resin volume, the volume ratio of the solution when the resin volume of the ion exchange resin is set to 1, hereinafter referred to as "RV").

[0131] In this disclosure, the flow rate when passing a solution through an ion exchange resin is defined by space velocity (the ratio of the volume of solution passed through the ion exchange resin per hour when the resin volume of the ion exchange resin is set to 1 (RV / h), hereinafter also referred to as "SV").

[0132] (Step 1) In Step 1, Na + Using 22 kL of UBK04 [DIAION (trademark), manufactured by Mitsubishi Chemical Corporation], a type of strongly acidic cation exchange resin, solution A was passed through and adsorbed onto UBK04 under conditions of 25°C or below and SV 0.682 RV / h. Subsequently, UBK04 was washed with 33 kL of ion-exchanged water.

[0133] 0.5 ± 0.1 mol / L of NaOH was passed through UBK04 to elute the adsorbed components. While measuring the Brix and pH at the UBK04 outlet during elution, the UBK04 pass-through (referred to as solution B) was passed through the WK40L column in the second step when the Brix reached 5.0 ± 1.0%. Subsequently, the passage to WK40L was terminated when the pH at the UBK04 outlet reached 12.0.

[0134] (Step 2) Next, H + Using 3.2 kL of WK40L (DIAION®, manufactured by Mitsubishi Chemical Corporation), a weakly acidic cation exchange resin of type 1, solution B was passed through WK40L under the condition of SV 4.545 RV / h.

[0135] The liquefaction from the WK40L resin column was collected from the point when the Brix reached 2.0% or higher. When solution B was depleted, water was added using deionized water, and the liquefaction from the WK40L column was collected until the Brix was 1.0% or lower and the cumulative amount of water added reached 15.0 ± 5.0 kL. This solution was designated as solution C.

[0136] (Third step) Next, 4.8 kL of the above solution C, adjusted to 12 ± 3°C using the acetic acid type strongly basic anion exchange resin PA412 (DIAION®, manufactured by Mitsubishi Chemical Corporation), was passed through the PA412 resin column under conditions of SV 1.042 RV / h. While measuring the Brix at the outlet of the PA412 resin column, the PA412 effluent was collected when the Brix reached 0.2%.

[0137] When solution C was depleted, water was added using deionized water until the Brix reached 1.0% or higher and the cumulative amount of water added reached 6.0 ± 3.0 kL. This 55.3 kL of PA412-passed liquid was then stirred and prepared as solution D.

[0138] (Step 4) Divide solution D into 27.8 kL and 27.5 kL, and add phosphoric acid (H 3 PO 475% was added to adjust the pH to 2.5-3.0, converting 5-aminolevulinic acid to 5-aminolevulinic acid phosphate. Solution D after pH adjustment was concentrated at a temperature below 40°C, and 2.02 kL of the concentrated solution was recovered and used as solution E (crystallization stock). At this time, 5-aminolevulinic acid phosphate crystals had precipitated in solution E, making accurate concentration measurement difficult. However, based on the 5-aminolevulinic acid phosphate concentration of the PA412 pass-through solution (31.5 g / L) and the degree of volume reduction due to concentration (concentrated from 55.0 kL to 2.02 kL), the 5-aminolevulinic acid phosphate concentration was estimated to be 857.7 g / L.

[0139] Solution E was introduced into the crystallization tank. While maintaining the temperature of solution E at 17.0 ± 3°C or below, methanol (MeOH) at a rate of 0.8 v / v / h relative to the volume of the crystallization stock solution was added to the crystallization tank, and the crystallization stock solution and methanol were mixed by stirring. The solution was aged for 2 hours while maintaining the temperature at 17°C or below and stirring, and a slurry of 5-aminolevulinic acid phosphate crystals was obtained.

[0140] The crystalline slurry was centrifuged to separate the 5-aminolevulinic acid crystals, and the wet crystals were washed with 360 L of methanol at room temperature. The washed 5-aminolevulinic acid phosphate crystals were used as part of the raw materials for Preparation Example 4.

[0141] [Preparation Example 2: Production of crystals with a high content of 5-aminolevulinic acid phosphate (coarse crystals)] (1A) Preparation process of crystallization stock solution (Step 0) Fermentation production of 5-aminolevulinic acid was carried out using recombinant Corynebacterium glutamicum according to the method of Japanese Patent Publication No. 2005-333907, and then sulfuric acid was added to adjust the pH to 3.0 ± 0.2. Subsequently, the culture broth was kept at 20 ± 10°C for 5 hours or more to inactivate the 5-aminolevulinic acid producing bacteria and to obtain a culture solution of 60.3 kL containing 35.6 g / L of 5-aminolevulinic acid.

[0142] Inactivated microbial cells were separated from the fermentation broth using a cross-flow filter (0.1 μm filter) to obtain 151.9 kL of a solution (referred to as Solution A) containing 14.4 g / L of 5-aminolevulinic acid.

[0143] As preparation example 2, the prepared solution A was subjected to ion exchange chromatography in the following first, second, and third steps.

[0144] (Step 1) In Step 1, Na + Using 22 kL of UBK04 (DIAION®, manufactured by Mitsubishi Chemical Corporation), a type of strongly acidic cation exchange resin, solution A was passed through and adsorbed onto UBK04 under conditions of 25°C or below and SV 0.682 RV / h. Subsequently, UBK04 was washed with 33 kL of ion-exchanged water.

[0145] A 0.5 ± 0.1 mol / L NaOH aqueous solution was passed through UBK04 to elute the adsorbed components. While measuring the Brix and pH at the UBK04 outlet during elution, the UBK04 pass-through (referred to as solution B) was passed through the WK40L column in the second step when the Brix reached 5.0 ± 1.0%. Subsequently, the passage to WK40L was terminated when the pH at the UBK04 outlet reached 12.0.

[0146] (Step 2) Next, H + Using 3.1 kL of WK40L (DIAION®, manufactured by Mitsubishi Chemical Corporation), a weakly acidic cation exchange resin of type 1, solution B was passed through WK40L under the condition of SV 4.545 RV / h.

[0147] While measuring the Brix at the outlet of the WK40L resin column, the liquefaction fluid was collected from the WK40L resin column once the Brix reached 2.0% or higher. When solution B was depleted, water was added using deionized water, and the liquefaction fluid from the WK40L column was collected until the Brix was 1.0% or lower and the cumulative amount of water added was 15.0 ± 5.0 kL. This solution was designated as solution C.

[0148] (Third step) Next, 4.8 kL of the above solution C, adjusted to 12 ± 3°C using the acetic acid type strongly basic anion exchange resin PA412 (DIAION®, manufactured by Mitsubishi Chemical Corporation), was passed through the PA412 resin column under conditions of SV 1.042 RV / h. While measuring the Brix at the outlet of the PA412 resin column, the PA412 effluent was collected when the Brix reached 0.2%.

[0149] When solution C was depleted, water was added using deionized water to push the solution back up until the Brix reached 0.2% and the cumulative amount of water pushed was 6.0 ± 3.0 kL. This 51.6 kL of PA412-passed liquid was then stirred and prepared as solution D.

[0150] (Step 4) Divide solution D into 26.2 kL and 26.1 kL, and add phosphoric acid (H 3 PO 4 75% by mass was added to adjust the pH to 2.5-3.0, converting 5-aminolevulinic acid to 5-aminolevulinic acid phosphate. Solution D after pH adjustment was concentrated at 40°C or below, and 3.00 kL of concentrated solution containing 597.8 g / L of 5-aminolevulinic acid was recovered and used as solution E (crystallization stock).

[0151] Solution E was introduced into the crystallization tank, and the temperature of solution E was adjusted to 17±3°C. Primary methanol at a rate of 0.6 v / v relative to the volume of the crystallization stock solution was added to the crystallization tank at a rate of 0.8 v / v / h, and the crystallization stock solution and primary methanol were mixed by stirring. 0.5 kg of 5-aminolevulinic acid phosphate crystals (powder, seed crystal) obtained in Preparation Example 1 was added to the solution, and the solution was aged for 2 hours while stirring and adjusting the solution temperature to 17±5°C.

[0152] At the completion of concentration, methanol at a rate of 0.8 v / v / h was added to the concentrated volume, and the crystallization stock solution and secondary methanol were mixed by stirring. While maintaining the solution temperature at 17 ± 3°C, stirring was continued for 2 hours after the completion of secondary methanol addition to obtain a slurry of 5-aminolevulinic acid phosphate crystals.

[0153] The crystalline slurry was centrifuged to separate the 5-aminolevulinic acid crystals, and the wet crystals were washed with 360 L of methanol at room temperature. The washed 5-aminolevulinic acid phosphate crystals were used as part of the raw materials for preparations 4 and 5.

[0154] [Preparation Example 3: Production of crystals with a high content of 5-aminolevulinic acid phosphate (coarse crystals)] (1A) Preparation process of crystallization stock solution (Step 0) Fermentation production of 5-aminolevulinic acid was carried out using recombinant Corynebacterium glutamicum according to the method of Japanese Patent Publication No. 2005-333907, and then sulfuric acid was added to adjust the pH to 3.0 ± 0.3. Subsequently, the culture broth was kept at 20 ± 10°C for 5 hours or more to inactivate the 5-aminolevulinic acid producing bacteria and obtain a culture solution of 57.3 kL containing 41.0 g / L of 5-aminolevulinic acid.

[0155] Inactivated microbial cells were separated from the fermentation broth using a cross-flow filter (0.1 μm filter) to obtain 144.3 kL of a solution (referred to as Solution A) containing 15.4 g / L of 5-aminolevulinic acid.

[0156] As preparation example 3, the prepared solution A was subjected to ion exchange chromatography in the following first, second, and third steps.

[0157] (Step 1) In Step 1, Na + Using 22 kL of UBK04 [DIAION (trademark), manufactured by Mitsubishi Chemical Corporation], a type of strongly acidic cation exchange resin, solution A was passed through and adsorbed onto UBK04 under conditions of 25°C or below and SV 0.682 RV / h. Subsequently, UBK04 was washed with 33 kL of ion-exchanged water.

[0158] 0.5 ± 0.1 mol / L of NaOH was passed through UBK04 to elute the adsorbed components. While measuring the Brix and pH at the UBK04 outlet during elution, the UBK04 pass-through (referred to as solution B) was passed through the WK40L column in the second step when the Brix reached 5.0 ± 1.0%. Subsequently, the passage to WK40L was terminated when the pH at the UBK04 outlet reached 12.0.

[0159] (Step 2) Next, H + Using 3.2 kL of WK40L [DIAION (trademark), manufactured by Mitsubishi Chemical Corporation], a weakly acidic cation exchange resin of type 1, solution B was passed through WK40 under the condition of SV 4.545 RV / h.

[0160] While measuring the Brix at the outlet of the WK40L resin column, the liquefaction fluid was collected from the WK40L resin column once the Brix reached 2.0% or higher. When solution B was depleted, water was added using deionized water, and the liquefaction fluid from the WK40L column was collected until the Brix was 1.0% or lower and the cumulative amount of water added was 15.0 ± 5.0 kL. This solution was designated as solution C.

[0161] (Step 3) Next, 4.8 kL of the acetic acid-type strongly basic anion exchange resin PA412 [DIAION (trademark), manufactured by Mitsubishi Chemical Corporation] was used to adjust the above solution C to 12 ± 3°C, and it was passed through the PA412 resin column under conditions of SV 1.042 RV / h. While measuring the Brix at the outlet of the PA412 resin column, the PA412 effluent was collected when the Brix reached 0.2%.

[0162] When solution C was depleted, water was added using deionized water until the Brix was 1.0% or less and the cumulative amount of water added reached 6.0 ± 3.0 kL. This 51.6 kL of PA412-passed liquid was then stirred and prepared as solution D.

[0163] (Step 4) Divide solution D into 25.9 kL and 25.7 kL, and add phosphoric acid (H 3 PO 4 75% by mass was added to adjust the pH to 2.5-3.0, converting 5-aminolevulinic acid to 5-aminolevulinic acid phosphate. Solution D after pH adjustment was concentrated at 40°C or below, and 3.00 kL of concentrated solution containing 567.1 g / L of 5-aminolevulinic acid was recovered and used as solution E (crystallization stock).

[0164] Solution E was introduced into the crystallization tank, and the temperature of solution E was adjusted to 17±3°C. Primary methanol at a rate of 0.6 v / v relative to the volume of the crystallization stock solution was added to the crystallization tank at a rate of 0.8 v / v / h, and the crystallization stock solution and primary methanol were mixed by stirring. 0.5 kg of 5-aminolevulinic acid phosphate crystals (powder, seed crystal) obtained in Preparation Example 1 was added to the solution, and the solution was aged for 2 hours while stirring and maintaining a temperature of 17±3°C.

[0165] At the completion of concentration, methanol at a rate of 0.8 v / v / h was added to the concentrated volume, and the crystallization stock solution and secondary methanol were mixed by stirring. While maintaining the solution temperature at 17 ± 3°C, stirring was continued for 2 hours after the completion of secondary methanol addition to obtain a slurry of 5-aminolevulinic acid phosphate crystals.

[0166] The crystalline slurry was centrifuged to separate the 5-aminolevulinic acid crystals, and the wet crystals were washed with 360 L of methanol at room temperature. The washed 5-aminolevulinic acid phosphate crystals were used as part of the raw materials for Preparation Example 5.

[0167] [Preparation Example 4: Production of crystals with a high content of 5-aminolevulinic acid phosphate (re-crystallization)] 20040 kg of wet crystals (powder) of 5-aminolevulinic acid phosphate obtained by the same method as in Preparation Examples 1 and 2 were used. The 5-aminolevulinic acid phosphate crystals (powder) were dissolved in deionized water at a concentration of 469.3 g / L, and the volume of the solution was made 4.5 kL. 20 kg of activated carbon was added to the 5-aminolevulinic acid phosphate solution, and the solution was decolorized for 30 minutes while maintaining a temperature of 8.3 to 8.7°C. The activated carbon was removed from the 5-aminolevulinic acid phosphate solution, and the decolorized filtrate was collected.

[0168] H + The decolorized filtrate was passed through a 2.1 kL chelate resin Lewatit® TP260 (manufactured by LANXESS). Recovery of the filtrate from the resin column began when the Brix at the outlet of the resin column reached 1.0%, and was stopped when the Brix rose and then fell to 1.0%. The recovered filtrate was 13.75 kL. Molecules with a molecular weight of 6,000 or more, such as proteins, that may be contained in the recovered filtrate from the resin column were removed using an ultrafiltration membrane, and the ultrafiltrate was recovered. The ultrafiltrate was concentrated at 40°C or below to obtain 3.3 kL of a crystallization stock solution of 5-aminolevulinic acid phosphate.

[0169] The crystallization stock solution was introduced into the crystallization tank, and its temperature was controlled to 15.5–18.4°C. Primary ethanol at a rate of 0.7 v / v / h relative to the volume of the crystallization stock solution was added to the crystallization tank, and the crystallization stock solution and primary ethanol were mixed by stirring. Subsequently, ethanol at a rate of 0.7 v / v / h relative to the volume of the crystallization stock solution after concentration was completed was added, and the crystallization stock solution and secondary ethanol were mixed by stirring. Stirring was continued for 2 hours after the end of secondary ethanol addition to obtain a slurry of 5-aminolevulinic acid phosphate crystals. The crystalline slurry was centrifuged to separate the 5-aminolevulinic acid crystals, and then washed with 440 L of ethanol at 20–30°C to obtain 5-aminolevulinic acid phosphate crystals. After that, the 5-aminolevulinic acid phosphate crystals were dried for 15 hours in a vacuum dryer with an internal temperature of 30°C.

[0170] [Preparation Example 5: Production of crystals with a high content of 5-aminolevulinic acid phosphate (re-crystallization)] 2094 kg of powdered wet crystals of 5-aminolevulinic acid phosphate obtained by the same method as in Preparation Examples 2 and 3 was used. 5-aminolevulinic acid phosphate crystals (powder) were dissolved in 4.5 kL of deionized water at a concentration of 464.8 g / L. 20 kg of activated carbon was added to the 5-aminolevulinic acid phosphate solution, and the solution was decolorized for 30 minutes while maintaining a temperature of 8.6 to 13.4°C. The activated carbon was removed from the 5-aminolevulinic acid phosphate solution, and the decolorized filtrate was collected.

[0171] H + The decolorized filtrate was passed through a 2.1 kL chelate resin Lewatit® TP260 (manufactured by LANXESS) using the mold. Recovery of the filtrate from the resin column began when the Brix at the outlet of the resin column reached 1.0%, and recovery of the filtrate from the resin column was stopped when the Brix initially rose and then decreased to 1.0%. The recovered filtrate was 13.8 kL. Molecules with a molecular weight of 6,000 or more, such as proteins, that may be contained in the recovered filtrate from the resin column were removed using an ultrafiltration membrane, and the ultrafiltrate was recovered. The ultrafiltrate was concentrated at 40°C or below to obtain 3.5 kL of crystallization stock solution with a 5-aminolevulinic acid phosphate concentration of 519 g / L.

[0172] The crystallization stock solution was introduced into the crystallization tank, and its temperature was controlled to 10.8–16.1°C. Primary ethanol at a rate of 0.7 v / v / h relative to the volume of the crystallization stock solution was added to the crystallization tank, and the crystallization stock solution and primary ethanol were mixed by stirring. 1 kg of 5-aminolevulinic acid phosphate crystals (powder) was added to the solution as seed crystals, and the mixture was stirred and allowed to mature for 36 minutes. At the point when the concentration was complete, ethanol at a rate of 0.7 v / v / h relative to the volume of the crystallization stock solution was added, and the crystallization stock solution and secondary ethanol were mixed by stirring. Stirring was continued for 2 hours after the end of the secondary ethanol addition, and a slurry of 5-aminolevulinic acid phosphate crystals was obtained. The crystalline slurry was centrifuged to separate the 5-aminolevulinic acid crystals, and then washed with 400 L of 100% ethanol at 20-30°C to obtain 5-aminolevulinic acid phosphate crystals. Subsequently, the 5-aminolevulinic acid phosphate crystals were dried for 15 hours in a vacuum dryer with an internal temperature of 30°C.

[0173] [Grinding and Quality Evaluation of 5-Aminolevulinic Acid Phosphate Crystals] Test Example 1 (Obtaining Unground Product) A portion of the 5-aminolevulinic acid phosphate crystals obtained in Preparation Example 4 (those not ground) was used as the unground product. The obtained mass was 192 kg. It was filled into fiber drums (FD) in approximately 10 kg increments.

[0174] Test Example 2 (Acquisition of Cutting Mill Product) The 5-aminolevulinic acid phosphate crystals obtained in Preparation Example 4 were filled into a hopper. A twin-screw paddle screw (LXS-2100, Kyowa Engineering Co., Ltd.) was connected to the hopper outlet, and a cutting mill (RCM-3 type, Ryoko Sangyo Co., Ltd.) was further connected to the outlet of the twin-screw paddle screw. A mesh with a mesh opening of 2.0 mm was attached to the outlet of the cutting mill. Using the twin-screw paddle screw, the 5-aminolevulinic acid phosphate crystals in the hopper were fed into the cutting mill, which was operated at a speed of approximately 250 kg / h for approximately 72 minutes at a frequency of 60 Hz, and ground. After grinding, the 5-aminolevulinic acid phosphate powder was filled into FDs in 10 kg increments. The acquired mass was 306 kg.

[0175] Test Example 3 (Acquisition of Pin-Milled Product) The 5-aminolevulinic acid phosphate crystals obtained in Preparation Example 4 were filled into a hopper. A twin-screw paddle screw was connected to the hopper outlet, and a pin mill (PHC-35 special type, Nishimura Machinery Works) was further connected to the outlet of the twin-screw paddle screw. A mesh with a mesh opening of 5.0 mm was attached to the outlet of the pin mill. Using the twin-screw paddle screw, the 5-aminolevulinic acid phosphate crystals in the hopper were fed into the pin mill, which was operated at a speed of approximately 100 kg / h for approximately 218 minutes at a frequency of 45 Hz, and ground. After grinding, the 5-aminolevulinic acid phosphate powder was filled into FDs in 10 kg increments. The acquired mass was 364 kg.

[0176] Test Example 4 (Obtaining Unground Product): A portion of the 5-aminolevulinic acid phosphate crystals obtained in Preparation Example 5 (those that were not ground) was used as the unground product. The obtained mass was 127.4 kg. It was filled into fiber drums (FD) in approximately 10 kg increments.

[0177] Test Example 5 (Acquisition of Cutting Mill Product) The 5-aminolevulinic acid phosphate crystals obtained in Preparation Example 5 were filled into a hopper. A twin-screw paddle screw was connected to the hopper outlet, and a cutting mill was further connected to the outlet of the twin-screw paddle screw. A mesh with a mesh opening of 2.0 mm was attached to the outlet of the cutting mill. Using the twin-screw paddle screw, the 5-aminolevulinic acid phosphate crystals in the hopper were fed into a cutting mill operated at a speed of approximately 250 kg / h for approximately 156 minutes at a frequency of 60 Hz for grinding. After grinding, the 5-aminolevulinic acid phosphate powder was filled into FDs in 10 kg increments. The acquired mass was 615 kg.

[0178] Test Example 6 (Acquisition of Pin-Milled Product) The 5-aminolevulinic acid phosphate crystals obtained in Preparation Example 5 were filled into a hopper. A twin-screw paddle screw was connected to the hopper outlet, and a pin mill (PHC-35 special type, Nishimura Machinery Works) was further connected to the outlet of the twin-screw paddle screw. A mesh with a mesh opening of 5.0 mm was attached to the outlet of the pin mill. Using the twin-screw paddle screw, the 5-aminolevulinic acid phosphate crystals in the hopper were fed into the pin mill, which was operated at a speed of 100 kg / h for approximately 447 minutes at a frequency of 45 Hz, and ground. After grinding, the 5-aminolevulinic acid phosphate powder was filled into FDs in 10 kg increments. The acquired mass was 745 kg.

[0179] Table 1A shows the results of measuring the ethanol content of the 5-aminolevulinic acid phosphate crystals (powder) obtained in Preparation Examples 4 and 5 using gas chromatography. The unground samples (Test Examples 1 and 4), cutting mill-ground samples (Test Examples 2 and 5), and pin mill-ground samples (Test Examples 3 and 6) were measured. Equal amounts of 5-aminolevulinic acid phosphate powder were weighed from five or more randomly selected fiber drums under each grinding condition and mixed to form a condensed product. The ethanol content of the condensed product was then measured.

[0180]

[0181] As shown in Table 1A, pin milling of 5-aminolevulinic acid phosphate crystals yielded a powder with an ethanol content reduced to less than half compared to unmilled or cutting milled products. Cutting milling did not reduce ethanol content significantly. Furthermore, as can be seen from Preparation Example 4, even if the ethanol content of the 5-aminolevulinic acid phosphate crystals before milling was nearly 2000 ppm, the final ethanol content was reduced to 600 ppm or less after pin milling.

[0182] Table 1B shows the results of gas chromatography analysis of the ethanol content of commercially available 5-aminolevulinic acid phosphate products (from companies A and B).

[0183]

[0184] As shown in Table 1B, several products on the market contain ethanol exceeding 1000 ppm. Therefore, powders obtained by conventional methods for producing 5-aminolevulinic acid phosphate powder contain residual ethanol derived from the purification process. On the other hand, in this disclosure, the ethanol content in the 5-aminolevulinic acid phosphate crystalline powder was reduced by performing pin mill grinding.

[0185] Using a particle size distribution analyzer, the particle size distribution of the 5-aminolevulinic acid phosphate powder inside each of the following materials obtained in Preparation Example 5—unground (corresponding to Test Example 4), cut-mill ground (corresponding to Test Example 5), and pin-mill ground (corresponding to Test Example 6)—was measured in multiple randomly selected fiber drums (FDs). From the measured values, the mean average particle size, the average standard deviation of particle size (for each FD), and the average standard deviation of particle size (between FDs) were calculated. The results are shown in Tables 2A to 2C.

[0186]

[0187]

[0188]

[0189] As shown in Tables 2A to 2C, pin milling yielded powders with smaller average particle size and standard deviation of particle size. The standard deviation was 175.3 μm for the unmilled product and 164.1 μm for the cutting mill-milled product, but decreased to 71.5 μm for the pin mill-milled product. Furthermore, pin milling also reduced the standard deviation of the average particle size between FDs for the 5-aminolevulinic acid phosphate powder.

[0190] Using a particle size distribution analyzer, the particle size distribution of products from Company A and Company B, the same products used for measuring ethanol content, was measured. From the measured values, the average particle diameter, the average standard deviation of particle diameter (for each lot), and the standard deviation of average particle diameter (between lots) were calculated. The results are shown in Table 2D (Company A) and Table 2E (Company B).

[0191]

[0192] As shown in Tables 2D and 2E, the average particle size and standard deviation were 177.7 μm and 145.5 μm for Company A's product, and 120.2 μm and 114.2 μm for Company B's product, respectively. From the above, it was found that by using pin milling, both the ethanol content and the standard deviation of particle size of 5-aminolevulinic acid phosphate powder can be reduced compared to commercially available products.

[0193] For each of the 5-aminolevulinic acid phosphate powders obtained in Preparation Example 5—unground (corresponding to Test Example 4), cut-mill ground (corresponding to Test Example 5), and pin-mill ground (corresponding to Test Example 6)—the specific volume of the 5-aminolevulinic acid phosphate powder inside was measured for several randomly selected freeze-dried units (FDs). The results are shown in Table 3A.

[0194]

[0195] As shown in Table 3A, the standard deviation of the crude specific volume for Preparation Example 5 was 0.44 mL / g for the unground product, 0.41 mL / g for the cutting mill-ground product, and 0.11 mL / g for the pin mill-ground product, with the pin mill-ground product showing the lowest value. Similarly, the standard deviation of the dense specific volume was 0.14 mL / g for the unground product, 0.11 mL / g for the cutting mill-ground product, and 0.06 mL / g for the pin mill-ground product, with the pin mill-ground product showing the lowest value.

[0196] Table 3B shows the results of measuring the specific volume of the same products from Company A and Company B that were used to measure the ethanol content.

[0197]

[0198] Test Example 7 (Acquisition of Pin-Milled Product) The 5-aminolevulinic acid phosphate crystals obtained in Preparation Example 5 (different from the crystals used in Test Example 6, but from a different FD) were filled into a hopper. A twin-screw paddle screw was connected to the hopper outlet, and a pin mill was further connected to the outlet of the twin-screw paddle screw. A mesh with a mesh opening of 5.0 mm was attached to the outlet of the pin mill. Using the twin-screw paddle screw, the 5-aminolevulinic acid phosphate crystals in the hopper were fed into a pin mill operated at a speed of 100 kg / h for approximately 60 minutes at a frequency of 45 Hz and ground. After grinding, the 5-aminolevulinic acid phosphate powder was filled into FDs in 10 kg increments. The acquired mass was approximately 100 kg.

[0199] The particle size distribution of the 5-aminolevulinic acid phosphate powder inside each obtained FD was measured. From the measured values, the mean average particle size and the average standard deviation of particle size (for each FD), and the average standard deviation of particle size (between FDs) were calculated. In addition, the specific volume of the aminolevulinic acid phosphate powder inside each obtained FD was measured, and the mean and standard deviation were calculated. The results are shown in Tables 4A and 4B.

[0200]

[0201]

[0202] The powder containing 5-aminolevulinic acid or a salt thereof according to this disclosure is a uniform powder with a small particle size, and therefore can be uniformly dispersed in formulations when used as a raw material for supplements, pharmaceuticals, and other products, and can also improve the stability in formulation. Furthermore, the powder according to this disclosure is less prone to quality variations even when mass-produced, making it useful as a raw material for supplements, pharmaceuticals, and other products. In particular, the manufacturing method according to this disclosure enables mass production of the above-mentioned uniform particle size powder using a simple procedure.

Claims

1. A powder containing 5-aminolevulinic acid or a salt thereof, wherein the average particle diameter calculated based on the number of particles in the particle size distribution is 230 μm or less, and the standard deviation of the particle diameter in the particle size distribution is 110 μm or less.

2. The powder according to claim 1, wherein the crude specific volume is 3.0 mL / g or less.

3. The powder according to claim 1, wherein the dense specific volume is 2.0 mL / g or less.

4. The powder according to any one of claims 1 to 3, wherein the content of each organic solvent is 1000 ppm by mass or less.

5. The powder according to claim 4, wherein the organic solvent is at least one selected from ethanol, methanol, isopropanol, n-propanol, acetone, and acetonitrile.

6. The powder according to any one of claims 1 to 3, wherein the ethanol content is less than 1,000 ppm by mass.

7. A method for producing a powder containing 5-aminolevulinic acid or a salt thereof, comprising the following steps (1) and (2): (1) A step of preparing crystals of 5-aminolevulinic acid or a salt thereof; (2) A step of grinding the crystals of 5-aminolevulinic acid or a salt thereof prepared in step (1) by impact grinding.

8. The manufacturing method according to claim 7, wherein the impact pulverization is performed by a high-speed rotary pulverizer.

9. The manufacturing method according to claim 8, wherein the high-speed rotary grinder is a fine grinder.

10. The manufacturing method according to claim 9, wherein the fine grinding machine is a pin mill.

11. The manufacturing method according to any one of claims 7 to 10, wherein the average particle diameter calculated based on the number of particles in the particle size distribution of the powder is 230 μm or less, and the standard deviation of the particle diameter in the particle size distribution is 110 μm or less.

12. The manufacturing method according to claim 11, wherein the crude specific volume of the powder is 3.0 mL / g.

13. The manufacturing method according to claim 11, wherein the dense specific volume of the powder is 2.0 mL / g.

14. The manufacturing method according to any one of claims 7 to 10, comprising carrying out crystallization using an organic solvent in step (1), wherein the content of each organic solvent remaining in the powder is less than 1,000 ppm by mass.

15. The manufacturing method according to claim 14, wherein the organic solvent is at least one selected from methanol, ethanol, isopropanol, n-propanol, acetone, and acetonitrile.

16. Powder of 5-aminolevulinic acid or a salt thereof, having a particle size of 230 μm or less and a standard deviation of 110 μm or less.

17. A method for producing powder of 5-aminolevulinic acid or a salt thereof having a particle size of 230 μm or less and a standard deviation of 110 μm or less, comprising the following steps (1) and (2): (1) A step of preparing powder of 5-aminolevulinic acid or a salt thereof. (2) A step of grinding the powder of 5-aminolevulinic acid or a salt thereof prepared in step (1) by impact grinding.